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SUMMARY.
This study has investigated the cardiovascular effects of long chain acyl 
carnitines and novel derivatives primarily using the coronary and mesenteric 
vascular beds, and thoracic aorta of the rat.
In the heart, long chain acyl carnitines caused an irreversible depression of 
myocardial contractility whilst exerting predominantly vasoconstrictor effects on the 
coronary vessels. Palmitoyl carnitine also caused vasoconstriction in quiescent 
mesenteric vessels, an effect not mediated via voltage-dependent calcium channels 
or c<-adrenoceptors, whilst having no effect on aorta. However, if vascular tone was 
artificially raised in mesenteric vascular beds using oc-adrenoceptor agonists, the 
vasoconstrictor response to palmitoyl carnitine was greatly potentiated, whereas if 
endothelin-1 was used to precontract the preparations palmitoyl carnitine elicited 
vasodilation. In contrast, the response to palmitoyl carnitine was very variable if 
high potassium was used to raise vascular tone. In precontracted aortae, however, 
palmitoyl carnitine produced less marked effects, eliciting small, gradual declines in 
vascular tone.
Esterification of palmitoyl carnitine changed the profile of activity of the 
drug from a vasoconstrictor to that of a potent dilator. Basic structural alterations of 
the molecule revealed that increasing the size of the ester group did not appreciably 
affect the activity of the drug, whereas increasing the fatty acyl chain length by two 
carbon atoms markedly reduced the vasodilator action. The vasodilator effects of the 
isopropyl ester of palmitoyl carnitine (PIP) were most marked in resistance vessels, 
such as the coronary and mesenteric vascular beds, the drug having little effect on 
the thoracic aorta. In the perfused heart the vasodilator action of P IP  did not appear 
to be mediated via the release of prostaglandins, EDRF or adenosine, activation of 
ATP-dependent potassium channels, or by stimulation of muscarinic or bradykinin 
B2-receptors.
In mesenteric vascular beds precontracted with phenylephrine, endothelin or 
high potassium, PIP1 elicited dose-related vasodilations, effects that were biphasic in 
the latter case. Additionally, in potassium-depolarised preparations this acyl 
carnitine ester also antagonized the contractile responses to calcium. In common 
with palmitoyl carnitine, PIP1 had less marked effects on precontracted aortae, and 
also had no action on guinea-pig taenia-coli preparation. Electrophysiological 
studies carried out using guinea-pig papillary muscle, taenia coli and rabbit ear 
artery indicated that PIP1 was without effect on resting membrane potential. Finally, 
the in vivo action of PIP1 was transient compared with verapamil which produced a 
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CHAPTER 1.
INTRODUCTION.
1) LONG CHAIN ACYL CARNITINES.
In recent years there has been considerable interest in the putative detrimental 
role of long chain acyl carnitines in the ischaemic myocardium. These fatty acid 
derivatives have been shown to accumulate in up to millimolar concentrations in the 
heart under conditions of ischaemia (Liedtke et al.,1978) whilst exogenous acyl 
carnitine has been shown to exert damaging biochemical, electrophysiological and 
mechanical effects (Adams et al.,1979; Knabb et al.,1986; Nakaya & Tohse,1986). 
Many of the studies so far, however, have involved the use of myocytes or 
subcellular fractions whilst little work has been carried out in intact hearts or 
isolated blood vessels. Therefore in the present study the effects of long chain acyl 
carnitines were examined in the Langendorff perfused heart, the mesenteric vascular 
bed and isolated aorta of the rat.
a) STRUCTURE & FORMATION.
Figure 1 illustrates the structure of palmitoyl carnitine, one of the major fatty 
acid metabolites that accumulates in the ischaemic heart. Long chain acyl carnitines 
are amphiphilic molecules in that they contain both hydrophobic and hydrophilic 
moieties and it has been suggested that many of their actions are simply due to this 
property (Idell-Wenger et al.,1978; Katz & Messineo,1981). The hydrophobic part 
of the molecule in this case is the long palmitoyl fatty acyl chain comprising 16 
carbon atoms whilst the positively charged quaternary nitrogen atom and carboxylic 
acid group confer the hydrophilicity of the compound. At low concentrations, 
amphiphiles exist in monomeric form and can influence membrane fluidity by 
inserting into the hydrophobic lipid environment (Watanabe et al.,1989), whilst at 
greater concentrations e.g. >13pM in the case of palmitoyl carnitine (Piper et 
al.,1984), this class of compound can aggregate into micelles. In these various states 
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Figure 1. The structure of palmitoyl carnitine.
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It has long been established that fatty acids are the preferential substrate of the 
myocardium and their metabolism in the heart is illustrated in figure 2. Free fatty 
acids taken up by the heart are rapidly esterified to fatty acyl CoA via a synthetase 
enzyme located on the outer mitochondrial membrane. Long chain acyl CoA does 
not readily cross the inner mitochondrial membrane and therefore the acyl group has 
to be transferred to a carrier molecule, carnitine, prior to ^ -oxidation. There are two 
carnitine acyl transferase enzymes (CATs) situated on either side of the inner 
mitochondrial membrane, as well as a translocase enzyme which is specific for the 
/-isomer (Wolkowicz et al.,1982). Initially the acyl CoA is converted to acyl 
carnitine on the outside of the inner mitochondrial membrane, which is then 
translocated across the membrane and then acyl CoA is reformed on the inner side 
of the membrane. This latter step also releases carnitine which then is recycled back 
across the membrane via the translocase enzyme. Under physiological conditions the 
acyl CoA in the mitochondrial matrix can then undergo yS -oxidation (Pande,1975) 
with the concomitant production of reduced nicotinamide adenine dinucleotide 
(NADH) and flavine adenine dinucleotide (FADH2) which can then generate 
adenosine triphosphate (ATP).
However, under ischaemic conditions oxygen availability is insufficient for 
oxidation of NADH and FADH2 and a build up of these reduced nucleotides occurs 
resulting in an inhibition of ^-oxidation (for review see Corr et al.,1984). 
Consequently this causes a build up of intermediates such as long chain acyl CoA 
and acyl carnitine, the former occuring almost exclusively in the mitochondrial 
fraction whilst the latter predominantly in the cytosol. Therefore, accumulating 
cytosolic long chain acyl carnitine is likely to have access to the sarcolemma in 
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1. Calcium Channel Activation.
In recent years it has been suggested that palmitoyl carnitine is an endogenous 
modulator of calcium channel function (Spedding & Mir,1987) on the basis that the 
effects of palmitoyl carnitine in K+-depolarised smooth muscle resemble those of 
the dihydropyridine Ca2+-channel activator, Bay K 8644. Previously it has been 
shown that palmitoyl carnitine augments myocardial calcium current in avian 
ventricular muscle, possibly via an effect on membrane surface charge (Inoue & 
Pappano, 1983). Further evidence for a modulatory role of this fatty acid metabolite 
on calcium channels has come from studies showing a positive inotropic effect of 
the drug at low concentrations (0.5-5pM) in chick myocytes, with higher 
concentrations reversing the inhibitory effects of the calcium antagonists, verapamil 
and nisoldipine (Duncan et al.,1986; Patmore et al.,1989). Recently it has been 
speculated that palmitoyl carnitine has a site of action at the sarcoplasmic reticulum 
in the heart, tightly linked to the calcium channel (Spedding et al.,1989).
2. Cardiac Electrophysiology.
Dysrhythmias induced by myocardial ischaemia are responsible for most sudden 
deaths due to coronary artery disease (Armstrong et al.,1972) and although these 
appear to arise from specific electrophysiological changes leading to ventricular 
fibrillation (Downar et al.,1977) the underlying mechanisms have not yet been 
elucidated. In 1981 Corr et al. proposed that long chain acyl carnitines may act as 
potential progenitors of dysrhythmias during ischaemia based on observations of the 
effects of exogenous acyl carnitine on canine Purkinje fibres. They found that 
palmitoyl carnitine induced a concentration-dependent decrease in maximum 
diastolic potential, amplitude, maximum rate of rise of the action potential, and 
action potential duration that was reversible after a washout period. These changes 
were analogous to those observed in ischaemic tissue in vivo (Downar et al.,1977). 
However, there are apparent discrepancies between studies depending on the type of
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tissue used and possibly also the species involved. For example, palmitoyl carnitine 
has also been shown to increase the duration of the action potential without 
changing diastolic membrane potential in chick ventricular muscle (Inoue & 
Pappano,1983) whilst shortening duration and decreasing resting potential in 
guinea-pig papillary muscle (Nakaya & Tohse,1986).
3. Enzyme Effects.
Over the past few decades long chain acyl carnitines have been shown to exert 
effects on a variety of enzymes, the observed action depending in many cases upon 
the concentration of drug used. For example, low concentrations of palmitoyl 
carnitine can stimulate Ca2+-ATPase activity whilst higher concentrations are 
inhibitory (Pitts et al.,1978; Adams et al.,1979). Similarly, this acyl carnitine exerts 
biphasic effects on the enzyme protein kinase C (Katoh et al.,1981; Wise & Kuo, 
1983). Many other enzyme inhibitory actions of palmitoyl carnitine have been 
documented including effects on the Na+/Ca2+ antiporter in sarcolemmal vesicles 
(Lamers et al.,1984), cardiac Na+/K+-ATPase (Adams et al.,1979), adenine 
nucleotide translocase (Shug & Subramanian, 1987) and adenyl cyclase (Abe et 
al.,1984). However, many of these observations have been made using high 
concentrations of palmitoyl carnitine that, when applied to the whole heart, can 
induce myoglobin loss and contracture (Hulsmann et al.,1985; Busselen et al.,1988). 
Therefore the results from these studies should be treated with caution when 
ascribing specific properties to this class of compound.
4. oc-adrenoceptors.
Increased oc-adrenoceptor numbers occur in the ischaemic myocardium of the 
cat and may contribute to the electrophysiological derangements observed under 
such conditions (Corr et al.,1981). Using hypoxic adult canine myocytes as a model 
of ischaemia, these workers demonstrated one possible mechanism responsible for 
the increase in myocardial ©cr adrenoceptors (Heathers et al.,1987). Acute hypoxia 
produced a two- to threefold reversible increase in cell-surface oc-adrenoceptors
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secondary to the sarcolemmal accumulation of long-chain acyl carnitines. 
Furthermore, inhibition of carnitine acyltransferase I, using sodium 2-[5-(4- 
chlorophenyl)-pentyl]-oxirane-2-carboxylate (POCA), prevented not only the accu­
mulation of acyl carnitine but also the exposure of the ex-adrenoceptor (Heathers et 
al.,1987). A similar finding has also been observed in the ischaemic rat heart (Allely 
& Brown,1988). Therefore another detrimental role for long chain acyl carnitines 
may exist in myocardial ischaemia. Interestingly, there has been a report recently 
showing that palmitoyl carnitine is able to facilitate pressor responses to 
noradrenaline in the caudal artery of the rat (Ugwu et al.,1987) and since acyl 
carnitines can freely cross membranes (Levitsky & Skulachev,1972) it is possible 
that these compounds producd in the cardiac myocytes will have access to the 
coronary circulation potentially affecting vascular oc j-adrenoceptors. Under
conditions of ischaemia, therefore, acyl carnitines may contribute to the 
vasoconstriction induced by circulating catecholamines.
5. Acyl carnitines and disease.
Long chain acyl carnitine levels are elevated under such conditions as 
ischaemia (Uedtke et al.,1978), diabetes (Feuvray et al.,1979), peripheral vascular 
disease (Hiatt et al.,1987) and fasting (Frohlich et al.,1978), however, their exact 
role in these situations and their potential to exert detrimental effects in vivo 
remains controversial. For example, despite the numerous effects of long chain acyl 
carnitines mentioned above, when examining the whole animal little is known about 
the local membrane concentration of these amphiphiles or the degree to which 
protein binding occurs, making extrapolation from in vitro data to the in vivo 
situation difficult. However, in recent years there has been interest in the potential 
therapeutic manipulation of acyl carnitine levels in disease states, primarily 
focussing on the prevention of accumulation of these fatty acid metabolites by 
inhibition of the enzyme carnitine acyl transferase 1 (CAT1).
Recendy, several studies have demonstrated that CAT1 inhibitors, POCA 
(Paulson et al.,1986), 2-tetraglycidic acid (TDGA) (Hekimian & Feuvray,1985) and
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oxfenicine (Molaparast-Saless et al.,1987) exert protective effects on the ischaemic 
myocardium. Whether this action is due to prevention of long chain acyl carnitine or 
CoA accumulation is contentious since other factors may additionally be involved. 
For example, the change from fatty acid oxidation to that of carbohydrate with a 
resultant decrease in the oxygen consumption of the heart may also account for the 
beneficial effects of CAT1 inhibitors. Furthermore, etomoxir (ethyl 2-[-6-(4-chloro- 
phenoxy)hexyl]oxirane-2-carboxylate), a more potent analogue of POCA, at low 
concentrations can inhibit accumulation of long chain acyl carnitines without 
exerting protective effects on the ischaemic heart, whilst 1000-fold higher 
concentrations do not prevent acyl carnitine accumulation in the heart but are 
protective (Lopaschuk et al.,1988). These protective effects of etomoxir may be 
attributable to its ability to increase glucose utilisation in the myocardium 
(Lopaschuk et al.,1989) and for this reason this drug is currently being tested as an 
antidiabetic agent (Eistetter & Wolf,1986). In conclusion, the potential of CAT1 
inhibitors in the treatment of disease states is at present speculative, however, two 
major problems have first to be overcome, namely the irreversibility of many 
currently available inhibitors and also their ability to produce cardiomyopathy at 
high doses (Spedding, 1990).
As mentioned previously, the detrimental role of long chain acyl carnitines in 
disease states remains contentious, at least until more concrete evidence can be 
obtained implicating these fatty acid metabolites as mediators of pathophysiological 
processes. However, both carnitine and its acyl derivatives have also been shown to 
have beneficial effects on the heart under certain conditions. So far much of the 
work has focussed on the protective effects of L-camitine on the myocardium of 
both experimental animals and man (Folts et al.,1978; Liedtke et al.,1979; Thomsen 
et al.,1979) including certain studies demonstrating an ability of this compound to 
reverse the detrimental electrophysiological effects of long chain acyl carnitines on 
the heart (Hayashi et al.,1981; Yokota et al.,1989). Similar salutary actions of short 
chain acyl carnitines such as propionyl(C3) and acetyKCy carnitines have also been 
documented (Paulson et al.,1984; Matsui et al.,1985; Subramanian et al.,1987)
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along with their taurine amide derivatives (Regitz et al.,1987). However, the precise 
involvement of carnitine and its derivatives remains unresolved, additionally 
complicated by studies demonstrating protective actions of long chain acyl carnitines, 





The main trigger for smooth muscle contraction is an elevation of the 
intracellular calcium concentration ([Ca2+]i). Not surprisingly, this is regulated by a 
large number of cellular processes, influencing the flux of calcium between three 
anatomical compartments; the extracellular space (ECS), cytoplasm and 
sarcoplasmic reticulum (SR) (for review see van Breemen & Saida,1989). Calcium 
influx into the cell from the ECS can be mediated i) by a passive leak across the 
plasma membrane, possibly as a consequence of non-specific disruption of the lipid 
bilayer, ii) via voltage-operated channels (VOCs) of which two types, “L” and “T”, 
have been identified in smooth muscle (Loirand et al.,1986), and iii) via 
receptor-operated channels (ROCs) (Bolton,1979). Conversely, flow of calcium out 
of the cell is carried out by the Ca2+/Mg2+-ATPase pump and to a variable extent 
via the Na+/Ca2+ antiporter. Similarly, calcium movement occurs between the SR 
and the cytoplasm, efflux via i) passive leak, ii) inositol 1,4,5-trisphosphate 
(ffy-activated channels and iii) Ca2+-activated channels, and entry into the SR 
driven by a Ca2+/Mg2+-ATPase pump (Eggermont et al.,1988).
At present there is some debate regarding the events responsible for the 
maintainance of contraction in smooth muscle. However, it is generally accepted 
that initiation of vascular contraction is due to a rise in intracellular calcium leading 
to an association of calmodulin (CaM) with myosin light chain kinase (MLCK), 
which then leads to the phosphorylation of myosin light chain and the formation of 
actin and myosin cross bridges resulting in tension development (Dillon et al.,1981). 
Prolonged exposure to a contractile agonist results in the maintainance of vascular 
smooth muscle in a sustained or ‘tonic’ contraction, however, in this state myosin 
light chain becomes dephosphorylated, ATP utilization and 0 2 consumption fall, 
and [Ca2+]i decreases to near basal levels. Consequently, this led to the hypothesis 
that a new type of long-lasting actin-myosin attachment could be formed i.e. ‘latch 
bridges’ formed between dephosphorylated myosin light chains and actin filaments.
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However, to date there is no molecular evidence for the existence of such latch 
bridges. Another hypothesis has been advanced to explain the sustained phase of 
smooth muscle contraction, implicating other intracellular proteins such as 
caldesmon, gelsolin and filamin in tension maintainance, with a modulatory role for 
the ubiquitous enzyme protein kinase C (Rasmussen et al., 1987).
b) ROLE OF THE ENDOTHELIUM.
The perception of the vascular endothelium has been radically altered over the 
past decade. It is now well established that the endothelial cell layer behaves as an 
organ, lining the entire vascular system and performing a plethora of functions, 
rather than merely providing a semi-permeable diffusion barrier. The endothelium 
exerts a modulatory influence on the coagulability and flow of blood in the vascular 
system, posseses synthetic activity e.g PGI2 synthesis (Weksler et al.,1985) and also 
metabolises a variety of substances including angiotensin I, bradykinin and adenine 
nucleotides (Ryan et al.,1976; Pearson & Gordon,1985). However, it was the 
seminal observations of Furchgott and Zawadzki in 1980 that delineated the 
importance of the endothelial cell layer in the modulation of vascular tone.
They first demonstrated the obligatory role of the endothelium in 
acetylcholine-induced relaxation of isolated arteries of the rabbit and suggested that 
some humoral factor(s), denoted endothelium-derived relaxant factor (EDRF), was 
responsible for this effect. Since then many substances have been identified that 
release EDRF including A23187 (Zawadzki et al.,1980), bradykinin (Cherry et 
al.,1981), thrombin (De Mey et al.,1982) and both saturated and unsaturated fatty 
acids (Cherry et al.,1983; Furchgott et al.,1985) whilst there has been much work 
directed toward identifying the chemical nature of EDRF, its endogenous 
precursor(s) and its mechanism of vascular relaxation (for review see Furchgott, 
1990).
In recent years it has been suggested that EDRF is in fact nitric oxide (NO) on 
the basis of the selective manipulation of its effects by various agents and the
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comparative chemical and biological properties of EDRF and NO (Ignarro et 
al.,1987; Palmer et al.,1987; Furchgott et al.,1988). Some data exists suggesting 
that EDRF differs from NO (Shikano et al.,1988) and that other factors are involved 
in endothelium-dependent relaxation such as endothelium-dependent hyperpolarising 
factor (EDHF) (Komori & Suzuki,1987; Feletou & Vanhoutte, 1988), however, the 
bulk of evidence to-date supports the identity of EDRF being nitric oxide.
EDRF is chemically unstable with a half-life ranging from 6s (Griffith et 
al.,1984) to 50s (Forstermann et al.,1986) and is probably broken down by 
superoxide anion (-0 2 ") released simultaneously in order to elicit autocatalytic 
destruction of the mediator (Gryglewski et al.,1986; Rubanyi & Vanhoutte,1986). It 
is thought to relax vascular smooth muscle by activation of soluble guanylate 
cyclase leading to accumulation of intracellular cyclic GMP (Rapoport et al.,1983). 
Many substances that interfere with EDRF directly or its target enzyme guanylate 
cyclase, have been used to either attenuate or enhance its effects, for example, 
superoxide dismutase potentiates the effects of EDRF by preventing its inactivation 
(Gryglewski et al.,1986) and haemoglobin inhibits EDRF-mediated responses, 
probably by chemically binding EDRF (Martin et al.,1986).
At present the source of nitric oxide in endothelial cells remains controversial. 
It has been suggested that L-arginine is the immediate precursor of NO, the 
formation being stereospecific and occuring from the terminal guanidino nitrogen 
atom(s) of the amino-acid (Palmer et al.,1988a). Supportive of this is that 
NG-monomethyl-L-arginine (L-NMMA), an L-arginine analogue, inhibits both the 
release of NO from aortic endothelial cells and the endothelium-dependent 
relaxation of rabbit aorta (Palmer et al.,1988b). However, it has also been 
demonstrated that L-NMMA is a non-specific inhibitor of a variety of other 
vasodilators (Thomas et al.,1989a) and it has been suggested that EDRF may be 
derived from sources other than L-arginine such as an arginine-containing moiety 
(Thomas & Ramwell,1988).
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The majority of research so far investigating effects of EDRF has been carried 
out on large, conduit blood vessels whilst few studies have concentrated on a 
possible role for EDRF in the microvasculature. In 1985, Owen & Bevan 
demonstrated that in peripheral rabbit arteries the acetylcholine-induced 
endothelium-dependent vasodilation increased as the vascular size decreased. Since 
then several studies have proposed a role for EDRF in the modulation of vascular 
tone in resistance vessels of the coronary circulation (Amezcua et al.,1989), kidney 
and mesenteric beds (Bhardwaj & Moore,1988; Moore et al.,1990).
c) RESISTANCE & CONDUIT VESSELS.
Most studies investigating the mechanisms of vascular smooth muscle 
contraction so far have focussed on large, conduit arteries such as the aorta despite 
the obvious physiological importance of resistance vessels. However, it appears that 
significant differences exist between these two types of blood vessels (Cauvin et 
al.,1984; Bevan et al.,1986).
Contractile agonists such as noradrenaline utilise both intracellular calcium and 
calcium influx from the extracellular space during activation of vascular smooth 
muscle (Deth & Van Breemen,1974; Bolton,1979) whilst high potassium-induced 
contractions are calcium influx-dependent (Van Breemen,1969). It seems that 
variation exists between blood vessels in the degree to which [Ca2+]i release and 
Ca2+ influx contribute to agonist-induced tone (Cauvin et al.,1983; Godfriand et 
al.,1986; Bevan et al.,1986). For example, there appears to be a lesser contribution 
of Ca2+ release from the sarcoplasmic reticulum and a greater sensitivity to calcium 
antagonists when activated by noradrenaline as the arterial size diminishes. In 
addition, there seems to be a functional heterogeneity between the sarcoplasmic 
reticulum from different sized blood vessels. In rabbit aorta, caffeine- and 
noradrenaline-induced release of 45Ca2+ into Ca2+-free solution are similar, whilst in 
mesenteric artery marked differences exist in the patterns of SR Ca2+-release 
(Leijten & Van Breemen,1984; Saida & Van Breemen,1984; Leijten & Van 
Breemen,1986).
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The importance of membrane depolarisation associated with receptor activation 
in vascular contraction also varies depending on the blood vessel and possibly 
species involved. For example, noradrenaline can activate the aorta without eliciting 
a change in membrane potential (Cauvin et al.,1984) whilst in smaller vessels the 
contraction to exogenous noradrenaline is accompanied by depolarisation (von Loh 
& Bohr,1973; Cauvin et al.,1984). Cauvin et al. (1984) showed that in rabbit 
mesenteric resistance vessels this depolarisation is completely inhibited by diltiazem 
whereas that induced by 80mM K+ is not, and suggested that it is the calcium ion 
entering through the ROCs that causes the membrane depolarisation rather than an 
initial depolarisation causing opening of VOCs. In addition, it has been proposed 
that in rat small mesenteric arteries the role of membrane potential in response to oc- 
adrenoceptor stimulation is not essential to but modulatory of the contractile 
response (Mulvany et al.,1982).
d) ACYL CARNITINES & BLOOD VESSELS.
Although long chain acyl carnitines have been subject to investigation for 
several decades, there have been very few studies examining the effects of these 
compounds on blood vessels. In 1986, Bigaud & Spedding demonstrated that 
palmitoyl carnitine increases sensitivity to Ca2+ in K+-depolarised rat aorta. This 
same group have since produced evidence that palmitoyl carnitine can facilitate 
pressor responses to noradrenaline in rat tail artery (Ugwu et al.,1987) advancing the 
hypothesis that this acyl carnitine is an endogenous calcium channel activator 
(Spedding & Mir,1987). However, the effects of palmitoyl carnitine on vascular 
tissue are likely to be complex. For example, depending on the concentration of 
drug used, palmitoyl carnitine can either elicit relaxations of precontracted rat aortae 
(<10pM) or produce direct contractile effects (>10pM), whilst also influencing the 
activity of exogenous endothelium-dependent vasodilators (Dainty et al.,1990).
It is possible that long chain acyl carnitines may exert effects on the coronary 
circulation since millimolar concentrations of these compounds have been reported 
in the ischaemic heart (Liedtke et al.,1978) and as these amphiphiles can readily
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cross lipid bilayers (Levitsky & Skulachev,1972) it is likely that they will have 
access to the coronary vessels. The initial aim of the present study was to examine 
the vascular effects of palmitoyl carnitine and related compounds, concentrating 
especially on resistance vessels e.g. coronary and mesenteric vascular beds, with a 
view to identifying any potential role for these lipid metabolites in the control of 
vascular tone. However, due to serendipitous discovery of novel vasodilator 
derivatives during the course of this research the work presented here is divided into 
two main sections; the vascular effects of the parent acyl carnitines, and the basic 




1. ISOLATED LANGENDORFF PERFUSED HEART PREPARATION.
Hearts from male Wistar rats (University of Bath strain), weighing between 
250-350g, were perfused by the Langendorff technique at a constant flow of 10 
mlmin-1 at 37°C with a modified Krebs-Henseleit solution of the following 
composition (mM): glucose 11.0; NaCl 118.0; NaH(X>3 25.0; KC1 4.7; KH2P04 1.2; 
CaCl2 1.2; MgS04 1.2, gassed with 95% 0 2, 5% C02. Following a 15 minute 
stabilisation period, the perfusate was changed to one containing 3.2mM K+ which 
raises coronary tone. Perfusion pressure changes were monitored with a Bell and 
Howell pressure transducer connected to a side-arm. Developed tension under a 
resting tension of 2g was recorded with a Devices isometric transducer attached to 
the apex of the heart; the signal from this transducer was also used to trigger an 
instantaneous rate meter. All recordings were made on a Gould 3000S recorder. 
Drug injections were made in volumes of less than lOOpl via a side-arm situated 
close to the aortic valves. Figure 3 illustrates the perfusion apparatus used in these 
experiments.
2. 86RUBIDIUM EFFLUX MEASUREMENT.
Hearts were perfused with Krebs-Henseleit solution (5.9mM K+) for a control 
period of 5 minutes, 86Rb (0.2pCi/ml) was then added for 10 minutes after which 
time it was washed out with control Krebs-Henseleit solution. After a further period 
of 30 minutes, the hearts were perfused with a modified solution containing 3.2mM 
K+ and the effluent collected 2 and 4 minutes later. After 5 minutes a standard dose 
of PCE (l-100nmoles) was added and further aliquots were collected for 15 
minutes. 1 ml of perfusate was added to 4 mis of scintillation fluid (Optiphase 
‘safe’) and counted in an LKB 1215 scintillation counter using an external standard 
channels ratio method for 10,000 counts or 10 minutes. At the end of the 
experimental period the heart was blotted with tissue paper, chopped into small 
pieces and left to dissolve in 5 mis of lMNaOH. After 48 hours the dissolved heart 
was neutralised with 5 mis of 1M HC1 to prevent chemiluminesence, and the decay 
during this period allowed for. Finally, 1 ml of the neutralised material was added to
16
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Figure 3. Diagram of the apparatus used for the isolated Langendorff perfused heart 
preparation.
4 mis of the scintillation fluid and counted.
3. ISOLATED PERFUSED MESENTERIC VASCULAR BED PREPARATION.
The superior mesenteric artery was cannulated, the middle colic artery ligated 
and the mesenteric vascular bed removed by careful dissection from male Wistar 
rats (University of Bath strain) weighing between 250-350g. Perfusion of the bed 
was carried out at a constant flow rate of 4 mlmim1 at 37°C with standard 
Krebs-Henseleit solution (5.9mM K+) gassed with 95% 0 2, 5% C02. Changes in 
perfusion pressure were monitored in a similar manner to that described above for 
the Langendorff heart preparation. Following dissection, tissues were left for an 
equilibration period of 30-40 minutes before drugs were added; injections of drugs 
(volume <|100pl) were made directly into the perfusate at a site close to the cannula.
In certain experiments the vascular tone was elevated artificially by inclusion of 
constrictor agents into the perfusion fluid, or by elevation of the potassium 
concentration of the Krebs-Henseleit solution. In the latter case, the sodium chloride 
in the solution was reduced accordingly to maintain osmolarity.
Additionally in some experiments, the vascular beds were perfused with a 
modified, calcium-free Krebs-Henseleit solution containing elevated potassium 
(llOmM; NaCl reduced to maintain osmolarity) for an initial equilibration period of 
30 minutes. Following this calcium chloride (0.1-10mM) was added cumulatively to 
the perfusion solution, the preparation allowed to recover in calcium-free solution 
for 40 minutes, and the addition of calcium chloride repeated. However, when 
assessing the effects of a drug on the contractile response to calcium, the drug was 
included in the perfusion solution for 20 minutes prior to the further addition of 
calcium.
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Wherever required, de-endothelialisation was achieved by rubbing the intimal 
surface of the aorta with a cotton bud.
4. THORACIC AORTA PREPARATION.
Segments of thoracic aorta of about 0.2cm length were prepared either as rings 
or as transverse strips, opened out along their longitudinal axes, and mounted for 
isometric tension recording under a resting tension of 2g in a tissue bath containing 
Krebs-Henseleit solution (5.9mM K+) gassed with 95% 0 2, 5% C02 at 37°C. 
Tissues were left for an equilibration period of 30-40 minutes before commencing 
the experiment. *
5. TAENIA-COLI PREPARATION.
Taenia preparations from the caecum of male guinea-pigs (350-450g) were set 
up in 10ml isolated organ baths containing standard Krebs-Henseleit solution 
(5.9mM K+) gassed with 95% 0 2, 5% C02 at 37°C. Contractions were measured 
using a Devices isometric tension transducer connected to a Lectromed Multitrace 2 
chart recorder. All preparations were mounted for recording under a resting tension 
of lg and initially left to equilibrate for 30 minutes before changing the bath 
solution to a modified, calcium-free Krebs-Henseleit solution for a further 30 
minutes. The effects of a drug on the contractile reponse to cumulatively added 
calcium chloride were assessed as described previously for the mesenteric vascular 
bed preparation (see above).
6. ELECTROPHYSIOLOGY
a) Guinea-pig Papillary Muscle.
All dissections were made in well oxygenated (95% 0 2, 5% C02) physiological 
salt solution (PSS) of the following composition (mM): NaCl 130.0; KC1 5.6; 
NaHC03 25.0; MgCl2 0.5; NaH2P04 0.6; glucose 11.0; CaCl2 2.16. Guinea-pigs 
were killed by stunning followed by cervical dislocation. Hearts were rapidly 
removed into well oxygenated PSS (room temperature) and the papillary muscles 
dissected free from the ventricles. These were then pinned out on Sylgard (Dow 
Coming) in a tissue bath (volume 1.5ml) perfused (13 ml/min) with PSS at 37°C.
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All tissues were left to equilibriate for 1-3 hours. Stimulation of papillary muscles 
was applied from an isolated stimulator (Digitimer DS2) via fine stainless steel pins 
placed close to one end of the preparation. Square pulses (0.05-lms; twice threshold 
voltage) were used to elicit action potentials. Intracellular recordings were made 
using glass microelectrodes of resistance 10-30 megohms. Records were amplified 
using a high impedance (1012 ohms) amplifier (Axoclamp-2) with capacity 
compensation. Action potentials (APs) were displayed on an oscilloscope (Gould 
OS4000) and analysed on-line by computer (Motorola 68000/Disc.Biol. on 
line-system) to give standard AP parameters i.e. resting potential, AP amplitude, 
maximum upstroke velocity (dv/dt max) and times to 50% and 90% repolarisations 
(APD50 and APD90, respectively).
b) Guinea-pig Taenia-coli and Rabbit Ear Artery.
For guinea-pig taenia-coli and rabbit ear artery preparations similar equipment 
and protocol were employed for the measurement of resting membrane potentials 
with the following exceptions. The preparations were not electrically stimulated 
during the experimental period and higher resistance glass electrodes were required 
to impale the tissues (50-80 megohms).
7. IN VIVO ANAESTHETISED jRAT PREPARATION.
Male Wistar rats (University of Bath strain), weighing 250-350g were 
anaesthetised using an intraperitoneal injection of sodium pentobarbitone (Sagatal, 
May & Baker) 60mgkg_1 body weight. A tracheal cannula was inserted and artificial 
respiration was maintained (ventilation rate 80mm'1, stroke volume lOmlkg*1) with a 
Miniature Starling (Bioscience) pump. Systemic arterial blood pressure was 
recorded from the left common carotid artery using a physiological pressure 
transducer (Gould P23 ID) coupled to a pressure processor amplifier (Gould 
13-4615-52) via a polythene cannula filled with heparinised saline (50UmH). The 
signal from the pressure transducer was also used to trigger an instantaneous rate 
meter for monitoring of heart rate throughout the experimental period. All
20
recordings were made using a Gould 3000S thermal chart recorder. A saline-filled 
polythene cannula was also inserted into the left jugular vein for administration of 
drugs. Rectal temperature was maintained at 37°C by means of a heating lamp.
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8) STATISTICAL ANALYSIS.
Results are expressed as the mean ± standard error of the mean (s.e.mean).
Statistical differences between means were assessed using either a paired or a 
non-paired Student’s t-test, where applicable.
9) MATERIALS.
The following compounds were used; (±) palmitoyl carnitine, (±) stearoyl 
carnitine, (±) myristoyl carnitine, palmitic acid, palmitoyl lysophosphatidylcholine, 
carnitine, phenylephrine, noradrenaline, angiotensin n , indomethacin, superoxide 
dismutase, L-NG-nitro arginine, atropine, adenosine, adenosine deaminase, 
mepacrine, bradykinin, sodium nitroprusside, glyceryl trinitrate, papaverine (Sigma), 
cromakalim, BRL38227 (Beechams), endothelin, D-Arg°[Hyp3,Thi5>8,D-Phe7]- 
bradykinin (Nova), glibenclamide (Hoechst), flurbiprofen (Boots), BW755C 
(Wellcome), methylene blue (Fisons), iloprost (Schering), clonidine (Gibbs), 
isoprenaline (Pharmax), phentolamine (Ciba), amyl nitrate (BDH), and verapamil 
(Abbot).
All novel compounds were synthesised by Dr. W.B.Wathey (University oj
Bath).
Drugs were prepared in distilled water, except cromakalim, BRL38227, 
glibenclamide and palmitic acid, which were first dissolved in ethanol and then 
diluted in distilled water; at the final concentration used the ethanol was without 
effect on the coronary circulation.
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CHAPTER 3.




Bolus injections of palmitoyl carnitine elicited large dose-related 
vasoconstrictions of the coronary vascular bed (figs 4 & 5) and at the highest doses 
used (30-100nmoles) small vasodilations were occasionally observed. This acyl 
carnitine also produced a cumulative, irreversible depression of myocardial 
contractility with no concomitant effect on heart rate. Other long chain acyl 
carnitines examined, myristoyl(C14) and stearoyl(C18), exhibited a similar profile of 
action (fig.6).
To assess whether these effects were specific, other amphiphilic compounds 
were investigated (fig.7). Palmitic acid (l-30nmoles) elicited biphasic responses 
consisting of a fast, initial vasoconstrictor phase followed by a later, variable 
vasodilator component. Palmitoyl lysophosphatidylcholine (LPC) (10-80nmoles), 
however, produced smaller vasoconstrictions of the coronary vessels than the long 
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Figure 4. Typical trace showing the effects of palmitoyl carnitine (l-300nmoles) on 
developed tension (DT), heart rate (HR) and perfusion pressure (PP) in the isolated 





























Figure 5. Effects of palmitoyl carnitine on perfusion pressure in the isolated 
perfused rat heart Vertical bars represent s.e.mean (w=4).
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Figure 6. Typical traces showing the effects of stearoyl (C18) and myristoyl (C14) 
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Figure 7. Typical traces showing the effects of palmitic acid (upper) and 
lysophosphatidylcholine (LPC) (lower) on perfusion pressure (PP) in the isolated 




In this vascular bed bolus injections of palmitoyl carnitine caused small 
dose-related increases in perfusion pressure (10-300nmoles) (fig.8). At higher doses 
there was a sustained rise in the resting tone of the mesenteric vessels (data not 
shown) and consequently any further experiments that required repeated dose- 
responses to the drug were restricted to lower doses of palmitoyl carnitine i.e. 
10-300nmoles. In addition, the compound was poorly soluble in distilled water at 
higher concentrations (>10'2M).
b) INTERACTIONS WITH VARIOUS VASOACTIVE AGENTS.
Long chain acyl carnitines have been reported to increase myocardial oc- 
adrenoceptor numbers (Heathers, et al., 1987), whilst their actions on vascular 
tissues have so far received little attention. Consequently, it was decided to 
investigate any possible interactions of palmitoyl carnitine with ©^-adrenoceptor 
agonists, such as phenylephrine and noradrenaline, using the perfused mesenteric 
vascular bed. Control dose-responses to palmitoyl carnitine were obtained and the 
tissue allowed to recover for 15 minutes at which time a pharmacological agent was 
introduced into the perfusion medium. A further 15 minutes later the dose-response 
to palmitoyl carnitine was repeated in the presence of the perfused agent. All 
responses are expressed as a percentage of the peak vasoconstriction obtained in the 
initial control dose-response to palmitoyl carnitine. Repeated additions of palmitoyl 
carnitine to the mesenteric vascular bed, in the absence of any other 
pharmacological agent, induced tachyphylaxis (fig.9) and consequently when 
assessing the effect of another drug on this vasoconstrictor action time-matched 
controls were employed.
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Figure 8. Typical trace showing the effects of palmitoyl carnitine (10-300nmoles) on 
perfusion pressure in the isolated perfused mesenteric vascular bed of the rat.




















Figure 9. Effects of repeated administration of palmitoyl carnitine (10-300nnoles) on 
perfusion pressure in the isolated perfused mesenteric vascular bed of the rat, 
shown as control (•) and 2nd dose-response (o) performed 15 minutes later. Vertical 
bars represent s.e.mean (n=9, *p<0.05) (100%=18.8±2.7mmHg).
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Responses of the mesenteric vascular bed to perfused potassium, noradrenaline 
and phenylephrine were obtained to determine submaximal concentrations of agonist 
required to precontract tissues when examining interactions with palmitoyl carnitine 
(data not included).
1. Adrenoceptor agonists.
Figure 10 shows the effect of the oc r adrenoceptor selective agonist 
phenylephrine on the vasoconstrictor action of palmitoyl carnitine in the mesenteric 
vascular bed. On addition of phenylephrine (10-5M) to the perfusion medium, a 
concentration that produced 70-80% maximal contractile response, the perfusion 
pressure rose sharply from a basal level of 33.0±2.4mmHg, reached a peak several 
minutes later, and then declined to a plateau of 145.2±4.6mmHg. The vasoconstrictor 
effect of palmitoyl carnitine was greatly potentiated in the presence of phenyleph­
rine, over a 400% increase being seen at the highest dose used, whilst a smaller late 
vasodilator component also became apparent although this varied in magnitude.
The perfusion presssure was affected in a similar manner by addition of 
noradrenaline (7pM) to the preparation as it was to phenylephrine; in this case the 
basal tone of the vascular bed was raised ffom a resting level of 31.5±l.lmmHg to 
141.5±3.1mmHg. Likewise, a marked potentiation of the vasoconstriction produced 
by palmitoyl carnitine occurred in the presence of noradrenaline, a non-selective 
adrenoceptor agonist (fig. 11).
The oc 2-agonist, clonidine, was also used to investigate whether a similar 
interaction occurred between palmitoyl carnitine and oc 2-adrenoceptor-mediated 
responses. Clonidine (106M) raised basal tone in the preparation to 71.0±5.8mmHg, 
and under these conditions the vasoconstrictor responses to palmitoyl carnitine were 
also greatly potentiated (fig. 12).
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Figure 10. a) Typical trace showing the effects of palmitoyl carnitine (10- 
300nmoles) on perfusion pressure (PP) in the isolated perfused mesenteric vascular 
bed of the rat precontracted with phenylephrine (lOpM). b) Effects of palmitoyl 
carnitine on perfusion pressure in phenylephrine-precontracted beds (o) (100%= 
15.5±2.6mmHg, n=9) compared with those in time-matched control preparations 













Figure 11. Effects of palmitoyl carnitine (10-300nmoles) on perfusion pressure in 
isolated perfused mesenteric vascular beds of the rat precontracted with 
noradrenaline (7pM) (o) (100% 29.0±0.6mmg, n=4) compared with those in 
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Figure 12. Effects of palmitoyl carnitine (10-300nmoles) on perfusion pressure in 
isolated perfused mesenteric vascular beds of the rat precontracted with clonidine 
(lpM) (o) (100%=18.2±2.3mmHg, n=4) compared with those in time-matched 
control preparations (•) (100%=18.8±2.7mmHg, n -9). Vertical bars represent 
s.e.mean (*p<0.05).
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Finally, to see whether there might be some interaction of palmitoyl carnitine 
with ^-adrenoceptors, some preparations were perfused with isoprenaline (10_5M) 
using the same protocol as before. Isoprenaline affected neither the basal tone of the 
preparation nor altered the response to palmitoyl carnitine (fig. 13).
In order to assess whether these potentiations were specific and not merely a 
result of raising the basal tone of the preparation, the effects of other vasoconstrictor 
agents on the action of palmitoyl carnitine were investigated.
2. Potassium.
Perfusion of the vascular bed with a modified Krebs-Henseleit solution 
containing 65mM potassium (sodium chloride reduced to maintain osmolarity) 
induced an increase of tone in the preparation from a resting value of 
34.6±1.7mmHg to 88.4±2.6mmHg. Figure 14 shows that at this potassium 
concentration there was no potentiation of the vasoconstrictor response to palmitoyl 
carnitine. In contrast to this, the situation in the presence of a higher potassium 
concentration was more complicated (fig. 15). Basal perfusion pressure in the 
vascular bed was raised from 32.6±3.1mmHg to 159.4±10.0mmHg by increasing the 
level of potassium to 1 lOmM in the perfusion medium. Under these conditions the 
responses to palmitoyl carnitine varied; at lower doses (10-30nmoles) 50% of the 
preparations exhibited vasoconstrictions and 50% vasodilations, a dose of 
lOOnmoles elicited vasoconstriction in 75% of tissues, whilst at the highest dose 
used (300nmoles) there was always a vasoconstrictor response of the mesenteric 
vessels to palmitoyl carnitine (fig. 15).
3. Endothelin.
Endothelin, a potent vasoconstrictor peptide, was also used to raise vascular 
tone in the mesenteric bed (fig. 16). Perfusion of this drug increased basal pressure 
from 36.8±2.3mmHg to 150.4±12.0mmHg although, in contrast to previous agents 






















Figure 13. Effects of palmitoyl carnitine (10-300nmoles) on perfusion pressure in 
isolated mesenteric vascular beds of the rat in the presence of isoprenaline (lOpM) 
(o) (100%=27.6±7.2mmHg, n -3) compared with those in time-matched control 
preparations (•) (100%=18.8±2.7mmHg, n=9). Vertical bars represent s.e.mean 
(*p<0.05).
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Figure 14. Effects of palmitoyl carnitine (10-300nmoles) on perfusion pressure in 
isolated mesenteric vascular beds of the rat precontracted with high potassium 
(65mM) (o, 100%=29.2±4.4mmHg, n -5) compared with those in time-matched 
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Figure 15. Sample traces illustrating the variability in response to palmitoyl 
carnitine (10-300nmoles) of perfusion pressure (PP) in isolated perfused mesenteric 
vascular beds precontracted with high potassium (llOmM) (n=8).
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Figure 16. Typical trace showing the effects of palmitoyl carnitine (10-300nmoles) 
on perfusion pressure (PP) in isolated perfused mesenteric vascular beds of the rat 
precontracted with endothelin (InM).
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slower rise in perfusion pressure. In the presence of endothelin (10'9M), palmitoyl 
carnitine now elicited dose-related dilations of the mesenteric vessels (figs. 16 & 
17a) which showed recovery at all doses tested. In some preparations these dilations 
were preceded by small vasoconstrictions, however, these were not significantly 
greater than control values (fig. 17b).
4. Angiotensin.
Another potent vasoconstrictor peptide, angiotensin II, was also investigated for 
possible interaction with palmitoyl carnitine. However, several different batches of 
drug tested were without effect on perfusion pressure in the isolated mesenteric 
vascular bed of the rat at concentrations of up to lOpM (n=6). Figure 18 shows the 
effect of angiotensin II on the vasoconstrictor action of palmitoyl carnitine; no 
potentiation of the response was observed.
c) EFFECT OF PHENTOLAMINE ON POTENTIATION OF VASCULAR 
RESPONSE TO PALMITOYL CARNITINE.
Having established that an interaction existed between palmitoyl carnitine and 
oc-adrenoceptor-mediated responses, the mechanism underlying this effect was 
investigated by examining the action of the competitive oc-adrenoceptor antagonist 
phentolamine, on the potentiation of the vasoconstrictor action of palmitoyl carnitine 
in the presence of phenylephrine. A similar protocol was adopted to previous 
experiments, except that following a plateau response to phenylephrine, 
phentolamine (10~7M), a concentration that maximally inhibited the contractile 
response to phenylephrine (lOpM) (n=4, data not shown), was introduced into the 
perfusion medium for 15 minutes. In the presence of phentolamine the basal 
perfusion pressure of the mesenteric vascular bed was reduced from 
147±12.6mmHg to 38.5±8.2mmHg, and under these conditions the vasoconstriction 
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Figure 17. a) Vasodilator effects of palmitoyl carnitine (10-300nmoles) expressed as 
% fall in perfusion pressure of induced vascular tone, in isolated perfused 
mesenteric vascular beds of the rat precontracted with endothelin (n=5). 
b) Constrictor effects of palmitoyl carnitine (10-300nmoles) in endothelin- 
precontracted mesenteric beds (o) (100%=20.4±5.2mmHg, n=5) compared with 
those in time-matched control preparations (•) (100%=18.8±2.7mmHg, n=9). 
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Figure 18. Effects of palmitoyl carnitine (10-300nmoles) on perfusion pressure in 
isolated perfused mesenteric vascular beds of the rat in the presence of angiotensin 
II (lOnM) (o) (100%=18.5±4.0mmHg, n=4) compared with those in time-matched 





















Figure 19. Effects of palmitoyl carnitine (10-300nmoles) on perfusion pressure in 
isolated perfused mesenteric vascular beds of the rat precontracted with 
phenylephrine (lOpM) and subsequently exposed to phentolamine (10_7M) (o) 
(100%= 13.8±1.9mmHg, n=4) compared with time-matched control preparations (•) 
(100% =18.8±2.7mmHg, n=9). Vertical bars represent s.e.mean (*p<0.05).
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d) EFFECT OF ANTAGONISTS ON THE VASCULAR RESPONSE TO 
PALMITOYL CARNITINE.
In order to investigate the mechanism of palmitoyl carnitine-induced 
vasoconstriction in the mesenteric vascular bed, the use of specific blocking agents 
was employed. The effects of phentolamine and verapamil were examined to assess 
the possible involvement of oc-adrenoceptor or calcium channel activation, 
respectively, in the action of palmitoyl carnitine. The protocol was the same as that 
used to study agonist interactions (see above) with the antagonists being in contact 
with the tissue for 10 minutes prior to repeating the dose-response to palmitoyl 
carnitine.
Figure 20a shows the effect of phentolamine on vasoconstrictor responses to 
bolus injections of phenylephrine in the mesenteric vascular bed. There is a parallel, 
rightward shift in the dose-response curve with increasing concentrations of 
phentolamine, as would be expected with this competitive oc-adrenoceptor 
antagonist; the concentration chosen for subsequent experiments was 10_8M. At this 
concentration there was no effect on the vasoconstrictor activity of palmitoyl 
carnitine (fig.20b).
Verapamil (0.5 & 5.0 pM) was perfused through the vascular bed and at neither 
concentration was there any blockade of the response to palmitoyl carnitine (fig.21).
e) EFFECT OF PERFUSED PALMITOYL CARNITINE ON RESPONSES TO 
PHENYLEPHRINE.
To further examine the interaction of palmitoyl carnitine with phenylephrine, 
the effect of perfused acyl carnitine on the vascular response to bolus injections of 
phenylephrine was investigated in the mesenteric vascular bed of the rat.
Dose-response curves to phenylephrine were constructed with time allowing 30 
minutes washout period between each curve. A typical trace of the vasoconstriction 
produced by phenylephrine is illustrated in figure 22a. Sensitivity of the mesenteric
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Figure 20. a) Control effects of phenylephrine (l-300nmoles) (•, n=4) on perfusion 
pressure and the antagonism of its constrictor action by phentolamine (10 8M) (▲, 
n=4) & 10_7M (a, n -4) in the isolated perfused mesenteric vascular bed of the rat 
(*p<0.05). b) Effects of palmitoyl carnitine (10-300nmoles) on perfusion pressure in 
the mesenteric vascular bed of the rat in the presence of phentolamine (10 8M) (4, 
100%=27.0±1.8mmHg, n=4) compared with those in time-matched control 
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Figure 21. Effects of palmitoyl carnitine (10-300nmoles) on perfusion pressure in 
the isolated perfused mesenteric vascular bed of the rat in the presence of verapamil 
0.5pM (A) & 5.0pM (A) (100%=28.5±2.4mmHg, n -8) compared with those in 
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Figure 22. a) Typical trace showing the effects of bolus injections of phenylephrine 
(l-100nmoles) on perfusion pressure (PP) in the isolated mesenteric vascular bed of 
the rat. b) Effects of repeated administration of phenylephrine (l-300nmoles) on 
perfusion pressure in the mesenteric vascular bed of the rat, shown as control (•), 
2nd (A ) & 3rd (y ) dose-response curves, performed with 30 minute intervals (/i=4).
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vessels to phenylephrine varied with time (fig.22b) so any subsequent experiments 
investigating possible interaction with palmitoyl carnitine, involved comparison with 
time-matched controls.
The effect of perfused palmitoyl carnitine on the vasoconstrictor action of 
phenylephrine is shown in figure 23. The response to phenylephrine was not altered 
by 10 6M palmitoyl carnitine, however, a ten-fold increase in acyl carnitine 
concentration resulted in a depression of the vasoconstriction at higher doses 
(30-300nmoles) and a significantly reduced maximal response to phenylephrine.
f) EFFECT OF LYSOPHOSPHATIDYLCHOLINE IN THE MESENTERIC 
VASCULAR BED.
The action of palmitoyl lysophosphatidylcholine (LPC), a structurally related 
amiphiphile to palmitoyl carnitine, was also investigated in the perfused mesenteric 
vascular bed. This compound (10-300nmoles) elicited small rises in perfusion 
pressure when applied as bolus injections to the quiescent bed (fig.24) similar to 
those observed with palmitoyl carnitine.
Using the previously described protocol, potential interactions between LPC and 
two vasoactive compounds, phenylephrine and endothelin, were examined. 
Phenylephrine (10_5M) raised the perfusion pressure from a basal level of 
37.2±3.5mmHg to 111.2±21.7mmHg (fig.24), and in the presence of this drug, LPC 
induced large biphasic responses; there were now dose-related vasoconstrictions 
followed by slower, more sustained relaxations of the mesenteric vasculature 
(fig.24). A similar profile of response was exhibited when vascular tone was raised 
using endothelin (109M) (fig.24). The peptide, endothelin, induced a much slower 
rise in perfusion pressure than did phenylephrine, increasing tone from 
34.0±3.3mmHg to 89.2±13.7mmHg, and biphasic responses were also observed to 
bolus injections of LPC in the presence of this agent. Both pressor agents caused a 
marked potentiation of the vasoconstrictor action of LPC (30-300nmoles) and there 
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Figure 23. Effects of palmitoyl carnitine on the vasoconstrictor action of 
phenylephrine (l-300nmoles) in the isolated perfused mesenteric vascular bed of the 
rat. Constrictor responses to phenylephrine in the presence of 10*6M (4, n=3) and 
10-5M (A,«=3) palmitoyl carnitine, included in the perfusion medium 15 minutes 
after the initial dose-response curve (#, n -4), are compared with time-matched 
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Figure 24. Typical traces showing the effects of lysophosphatidylcholine (LPC) (•, 
10-300nmoles) on perfusion pressure (PP) in isolated perfused mesenteric vascular 
beds of the rat precontracted with phenylephrine (lOpM) («=4) {upper trace) and 
endothelin («=4) {lower trace).
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Figure 25. Effects of lysophosphatidylcholine (10-300nmoles) on perfusion pressure 
in the isolated perfused mesenteric vascular bed of the rat precontracted with either 
phenylephrine (lOpM) (A, n -4) or with endothelin (InM) (o, n=4) compared with 




Following experiments carried out in fine resistance vessels i.e. coronary and 
mesenteric vascular beds, the effects of palmitoyl carnitine on a larger blood vessel, 
the thoracic aorta, were investigated. Palmitoyl carnitine (l-64pM) had no effect on 
quiescent transverse aortic strips and at the higher concentrations tension recording 
was impaired by foaming of the organ bath due to the compound’s detergent 
properties (data not shown, n=4).
b) INTERACTIONS WITH VARIOUS VASOACTIVE AGENTS.
Due to the lack of action of palmitoyl carnitine on the quiescent aorta, the 
effect of raising the basal tone of the preparation, to perhaps manifest some relaxant 
activity of the compound, was investigated. Initially this was performed using 10’7M 
phenylephrine, a concentration that produced a 70-80% maximal contractile 
response in the tissue. Following a stable plateau rise in tension to phenylephrine, 
the integrity of the endothelium was tested by addition of acetylcholine (lpM); less 
than 80% relaxation of the aortic strip was taken to be indicative of endothelial cell 
damage and these preparations rejected. The tissues were then washed and, 
following a period of recovery, were recontracted with phenylephrine.
Palmitoyl carnitine caused a gradual relaxation of the aorta in those tissues that 
possessed an intact endothelium (fig.26). Again, higher concentrations of the drug 
produced a foaming of the organ bath impairing accurate assessment of its action. In 
some tissues the endothelium was mechanically removed, and this significantly 
attenuated the relaxant effect of palmitoyl carnitine (fig.26). In addition, control 
preparations were set up in which phenylephrine was in contact with the tissues for 
the duration of the experimental period in the absence of palmitoyl carnitine; under 
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Figure 26. Relaxant effects of palmitoyl carnitine (0.3-64pM) on rat aorta 
precontracted with phenylephrine (107M) either with endothelium (#, 
100%=0.75±0.02g («=7)) or without endothelium (o, 100%=0.88±0.06g («=7)), 
with endothelin (InM) (■, 100%=0.38±0.07g («=4), or with high potassium 
(llOmM) ( a , 100%=0.73±0.09g (w=4)).
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High potassium (llOmM) was also used to raise tone in aortic preparations and 
in this instance tissues were prepared as rings. The rise in tension elicited by 
potassium was comparable to that of phenylephrine, however, palmitoyl carnitine 
did not relax the tissues to such an extent in the presence of this agent (fig.26 & 
27). However, in the presence of high potassium the integrity of the endothelium 
was difficult to assess as relaxation to acetylcholine is virtually abolished (Taylor et 
al.,1988).
In certain preparations vascular tone was raised using endothelin-1 (10*9M), and 






•  •  •
-*• ro °  o  o
KCL(110mM)
•  •oo





Figure 27. Typical trace showing the effects of palmitoyl carnitine (0.5-64pM) on 




It has been suggested that long chain acyl carnitines can act as endogenous 
mediators of myocardial damage during ischaemia in view of their accumulation 
under such conditions (Liedtke et al., 1978; Corr et al., 1984) and ability to produce 
effects similar to those observed during ischaemia in vivo when applied exogenously 
to tissues in vitro (Corr et al., 1984). The detrimental effects of acyl carnitines on 
the heart are confirmed by the present study in which palmitoyl carnitine caused an 
irreversible depression of contractility in the Langendorff perfused rat heart when 
administered as bolus injections. However, conflicting reports exist regarding the 
action of palmitoyl carnitine and related compounds on the myocardium. For 
example, a positive inotropic action of palmitoyl carnitine has been demonstrated in 
avian ventricular muscle (Inoue & Pappano, 1983) and in chick myocytes (Patmore 
et al., 1989), whilst other workers have reported opposite effects on contractility in 
perfused hearts (Hulsmann et al., 1985; Busselen et al., 1988). This large variation 
in reported effects of long chain acyl carnitines on myocardial contractility may 
have arisen due to differences in the concentration of drug used (Nakaya & Tohse, 
1986), mode of application, experimental conditions or perhaps more importantly 
the particular tissues investigated. In this present study, however, the putative 
detrimental role of long chain acyl carnitines in the myocardium is supported.
In contrast to the many reports regarding the action of long chain acyl 
carnitines on isolated cells, subcellular fractions or purified enzyme systems, there 
have been few studies examining the effects of such compounds on intact blood 
vessels. In the isolated perfused Langendorff heart palmitoyl, myristoyl and stearoyl 
carnitines exerted a predominantly vasoconstrictor action on the coronary 
circulation, whereas carnitine itself was without effect on the coronary vessels, 
suggesting that a fatty acid chain is required for the vascular activity of the 
molecule. In other vascular preparations examined, palmitoyl carnitine elicited 
primarily a vasoconstrictor response, however, a certain degree of relaxant activity 
was observed with this compound in situations where vascular tone had been 
artificially raised, for example, in endothelin-precontracted mesenteric vascular 
beds. The few existing reports regarding the action of acyl carnitines on blood
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vessels appear essentially to be in accord with the present observations of the 
constrictor effects of these compounds. For example, Bigaud and Spedding (1986) 
observed that palmitoyl carnitine contracted rat aorta, whilst other studies have 
demonstrated that low concentrations of palmitoyl carnitine facilitated pressor 
responses to noradrenaline in the rat caudal artery (Ugwu et al., 1987) and that 
preincubation with the carnitine acyl transferase inhibitor POCA (sodium 
2[5-(4-chlorophenyl)-pentyl]oxirane-2-carboxylate) prevented the hypoxia-induced 
augmentation of contractions to KC1 in rat portal vein (Fasehun et al., 1987). In the 
present study, however, palmitoyl carnitine was without effect on the quiescent 
aorta, a discrepancy with the above study that may have arisen due to differences in 
experimental conditions. For example, Bigaud and Spedding (1986) used a 
Krebs-Henseleit bathing solution containing 12mM K+ in contrast to the lower 
concentration of 5.9mM K+ used here, whilst also applying higher concentrations of 
the acyl carnitine.
Another feature of the vascular action of palmitoyl carnitine was that the 
magnitude of the vasoconstrictor response varied according to the blood vessels on 
which the drug was acting; it produced a powerful coronary vasoconstriction, a 
weaker effect on the mesenteric vessels and no effect on the quiescent aorta. This 
may therefore reflect a degree of vascular selectivity of the drug for fine resistance 
vessels, however, these results may also arise as a consequence of differences in 
mode or rate of delivery of compound to the tissues.
Two fundamental questions arise from the preceding observations; how does 
palmitoyl carnitine produce its vascular effects and why does such variation exist in 
its action with regard to different blood vessels? Palmitoyl carnitine is an 
amphiphile, a molecule that contains both hydrophobic and hydrophilic moieties, a 
long palmitoyl chain and the charged quaternary nitrogen and carboxyl groups, 
respectively, and previously it has been suggested that the biological effects of these 
fatty acid derivatives are attributable to this amphiphilic property (Idell-Wenger et 
al., 1978; Katz & Messineo, 1981). Amphiphiles at low concentrations exist as
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monomers and can insert into the hydrophobic environment of the lipid membrane 
thereby influencing fluidity (Watanabe et al., 1989), whilst at higher concentrations, 
>13pM, this class of compound can aggregate into micelles (Piper et al.,1984), in 
which the hydrophilic regions of the molecule remain in contact with the aqueous 
medium and the lipophilic portions are clustered in a hydrophobic core. In these 
various states amphiphiles can physically disrupt the lipid membrane via a 
non-specific “detergent” action. In addition, it has been suggested that as a 
consequence of such incorporation into membranes amphiphiles may displace Ca2+ 
ions from negatively charged binding sites on the membrane phospholipids (Katz & 
Messineo, 1981; Philipson et al., 1985) and modulate the function of integral 
membrane proteins by influencing the local lipid environment (Helenius & Simons, 
1975; Sanderman, 1978). Furthermore, there have been a large number of studies 
carried out regarding the actions of long chain acyl carnitines on various enzymes 
including Na+/K+-ATPase (Adams et al., 1979; Owens et al., 1982), sarcoplasmic 
reticulum Ca2+-ATPase (Pitts et al., 1978; Adams et al., 1979) and protein kinase C 
(Katoh et al., 1981), and it has been suggested that many of these effects may 
simply be due to non-specific membrane disruption allowing increased permeability 
to both Na+ and Ca2+ ions (Lamers et al., 1984).
Can such non-specific amphiphilic actions, therefore, be responsible for the 
effects observed with palmitoyl carnitine in this present study? Certainly membrane 
disruption allowing leakage of ions across the bilayer would tend to cause an influx 
of extracellular calcium ions resulting in constriction of blood vessels, as seen in the 
coronary and mesenteric vascular beds, however, palmitoyl carnitine should have 
exerted a similar constrictor action on the rat aorta as well. In addition, this acyl 
carnitine was also capable of eliciting relaxations of vascular tissue under certain 
conditions, suggesting a more complex profile of activity than that resulting purely 
from the compound’s amphiphilic nature. Moreover, another amphiphile, palmitic 
acid, has been shown to dilate the coronary circulation (Hulsmann, 1976) and in this 
present study displayed effects distinct from those of its corresponding carnitine 
derivative. Several workers have also concluded that non-specific detergent effects
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of palmitoyl carnitine are insufficient to account for its actions in certain 
experimental conditions, including effects on mitochondrial disruption following 
ischaemia (Piper et al., 1984) and interactions with calcium channels (Spedding & 
Mir, 1987).
It appears likely, therefore, that there are more specific mechanisms underlying 
the effects of long chain acyl carnitines, and there are many possible targets for the 
action of palmitoyl carnitine including membrane calcium channels, intracellular 
calcium movement, second messenger systems, enzymes and contractile proteins.
In recent years it has been suggested that palmitoyl carnitine may be an 
endogenous activator of calcium channels (Spedding & Mir, 1987). Previously it has 
been shown that amphiphiles can affect calcium binding (Philipson et al., 1985) and 
that palmitoyl carnitine increases the calcium current in avian ventricular muscle via 
an effect on membrane surface charge (Innoue & Pappano, 1983). In 1987, 
Spedding and Mir demonstrated that this acyl carnitine resembled Bay K8644, the 
calcium channel activator, in its contractile effects on K+-depolarised taenia coli 
preparations and in its selective displacement of tritiated calcium antagonists in 
binding studies using rat brain, although differences in potency between these two 
compounds were apparent. They suggested that palmitoyl carnitine was interacting 
either directly with the voltage sensitive channel (VOC) or with tightly associated 
lipids (Spedding & Mir, 1987), however, they also expressed the need for caution in 
interpretation of results due to the amphiphilicity of the compound. Whether a 
specific activation of voltage sensitive calcium channels or a decrease in surface 
charge, leading to movement of extracellular calcium into the cell, the resultant 
action of palmitoyl carnitine in blood vessels would be to elicit vasoconstriction, an 
effect observed in the present study in both mesenteric and coronary vascular beds. 
The involvement of VOCs in the action of palmitoyl carnitine in the mesenteric 
vascular bed of the rat, however, appears doubtful in the present study since its 
vasoconstrictor action was not attenuated by verapamil, at a concentration known to 
inhibit contractions to high potassium in this preparation (Kondo et al., 1980).
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Another possible explanation of the vasoconstrictor action of palmitoyl carnitine 
may be that of specific receptor activation. As endogenous acyl carnitine 
preferentially accumulates in the sarcolemma (Knabb et al., 1986) it is possible that 
specific binding sites may exist on the cell membrane linked to ionic channels or to 
second messenger processes. Previously it has been suggested that many constrictor 
agents stimulate influx of extracellular calcium into the cell via common 
“receptor-operated” calcium channels (ROCs) that are distinct from VOCs (Bolton, 
1979; van Breemen et al., 1979). There have been reports showing that 45Ca2+ entry 
into cultured aortic smooth muscle cells upon agonist stimulation occurs via 
pathways that are insensitive to dihydropyridines (Wallnofer et al., 1987; Zschauer 
et al., 1987) although the mechanisms and second messengers involved in mediating 
this effect are still unclear. It is possible, therefore, that palmitoyl carnitine may 
activate specific receptors linked to ROCs, thereby stimulating calcium entry into 
the cell and causing vasoconstriction, however, this action might also have been 
expected to be affected by verapamil in the present study as this calcium antagonist 
attenuates the response to noradrenaline in the rat mesenteric artery (Kondo et al., 
1980).
Palmitoyl carnitine can freely cross lipid membranes (Levitsky & Skulachev, 
1972) and may therefore have an intracellular mode of action, perhaps causing 
release of calcium from stores in a manner similar to caffeine (Leijten & van 
Breemen, 1984; Kanaide et al, 1987), inhibition of calcium sequestration, or maybe 
affecting intracellular second messenger systems. Contractile agonists such as 
noradrenaline have been shown to increase cellular levels of inositol triphosphate 
(IP3), derived from membrane phospholipid hydrolysis, which causes mobilisation 
of intracellular calcium from sarcoplasmic reticulum (Berridge & Irvine, 1984) and 
it is possible that palmitoyl carnitine may exert its vasoconstrictor action in a similar 
manner. However, it appears more likely that palmitoyl carnitine would interact 
with pathways affected by the other product of phosphoinositide hydrolysis, 
diacylglycerol (DAG), in view of the structural similarities between the two 
compounds. DAG is an activator of protein kinase C (Nishizuka, 1984), an enzyme
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which phosphorylates a number of intracellular proteins including myosin light 
chain kinase (MLCK) (Ikebe et al., 1985), smooth muscle myosin light chain (Endo 
et al., 1982) and the oc-adrenoceptor (Sibley et al., 1984), and additionally has 
recently been postulated to increase the calcium sensitivity of the myofilaments 
(Kamm & Stull, 1989; Sugiura et al., 1989). However, conflicting reports have 
appeared regarding the action of palmitoyl carnitine on protein kinase C, for 
example, palmitoyl carnitine has been shown to inhibit the purified enzyme from 
bovine heart (Wise & Kuo, 1983) whilst causing activation in rat mast cells 
(Grosman, 1988). Phorbol esters such as phorbol 12,13-dibutyrate (PDB), which 
activate protein kinase C, have been shown to exhibit contractile effects on isolated 
blood vessels (Danthuluri & Deth, 1984; Rasmussen et al., 1984) and therefore it is 
possible that the vasoconstrictor action of palmitoyl carnitine observed in the 
present study may be explained by such a mechanism. There are many further 
possibilities to explain the vasoconstrictor action of palmitoyl carnitine including 
effects on intermediates in the contractile process such as calmodulin, although 
aliphatic amphiphiles have been shown to exert an inhibitory action on 
calmodulin-activated processes (Isomaa et al., 1989), or direct effects on smooth 
muscle contractile proteins.
The apparent selectivity in the effects of palmitoyl carnitine with respect to 
blood vessels may be due to differences in the mechanism(s) involved in the 
contractile proccesses of different vessels or perhaps may arise as a consequence of 
the mode of application of the drug. Firstly, there are known to be differences in the 
involvement of intracellular calcium release in response to certain contractile agents 
e.g. noradrenaline, between fine resistance vessels, as contained in the mesenteric 
and coronary vascular beds, and large conductance vessels such as the thoracic aorta 
(van Breemen & Siegel, 1980; Cauvin et al., 1982). Cauvin et al. (1982) 
demonstrated that the contribution of calcium release from intracellular sites to 
noradrenaline-mediated activation decreases while that of calcium influx increases, 
when moving from conduit to resistance vessels. Thus differences in the effects of 
palmitoyl carnitine, either directly or indirectly, on calcium influx via potential-
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insensitive pathways may account for its seemingly more profound action on fine 
resistance vessels. Alternatively, there may be differences in sensitivity of 
intracellular enzymic pathways or second messenger systems to palmitoyl carnitine 
between conduit and resistance vessels, or perhaps variation in the contractile 
proteins involved in the development of vascular tone. For example, major proteins 
such as caldesmon, gelsolin, filamin and desmin are abundant in smooth muscle and 
may play an important role in contraction (Rasmussen et al., 1987) as well as the 
more widely recognised calmodulin and myosin light chain kinase. However, the 
apparent selectivity in the effects of the acyl carnitine may alternatively be due 
simply to a difference in the mode of application of the drug. For example, the flow 
rate used in the present study for perfusion of the coronary vascular bed was greater 
than that for the mesenteric vascular bed, potentially allowing a higher concentration 
of drug to arrive at the tissue when administered as a bolus injection into the 
perfusion stream. In contrast, palmitoyl carnitine was applied to aortic tissue as 
cumulative additions to the organ bath, exposing the tissue to steadily increasing 
concentrations of drug.
Although the predominant action of palmitoyl carnitine is that of 
vasoconstriction, a certain degree of vascular relaxant activity was associated with 
this drug under conditions of artificially elevated vascular tone e.g. in the coronary 
circulation in which tone had been increased using modified Krebs-Henseleit 
solution containing 3.2mM K+, in mesenteric vascular beds perfused with various 
agents such as endothelin, and in certain precontracted aortae. Palmitoyl carnitine 
has previously been shown to exert biphasic effects on many enzymes including 
Na+/K+-ATPase and Ca2+-ATPase (Adams et al., 1979), the effects being dependent 
on the concentration of drug used, and it is not surprising therefore that both 
contractile and relaxant actions were observed in the present vascular studies. 
However, there appears to be a great deal of variation in the response elicited by 
palmitoyl carnitine, depending on both the vascular preparation used and the agent 
used to precontract the tissue. For example, large relaxations of the mesenteric 
vascular bed were caused by palmitoyl carnitine in the presence of endothelin,
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whereas it did not relax endothelin-precontracted aortae. Furthermore, if high 
concentrations of potassium were used to precontract the mesenteric vascular bed, 
the response to palmitoyl carnitine varied within a single preparation and also 
between tissues, the compound eliciting a seemingly random mixture of 
vasoconstrictions and dilations. This latter effect may perhaps have been due to 
differences in the integrity of the mesenteric vascular endothelial cell layer, or many 
other factors such as variation in the lipid content of cell membranes between 
animals.
The most striking relaxant effect of palmitoyl carnitine was observed in 
mesenteric vascular beds that had been precontracted with the peptide endothelin. 
This may indicate a latent vasodilator property of palmitoyl carnitine manifested as 
a result of the increase in resting tone of the preparation, or may indicate a more 
specific interference with some aspect of the mechanism whereby endothelin 
maintains vascular contraction. It is possible that these relaxations of endothelin- 
precontracted mesenteric beds may be in part a result of protein kinase C inhibition, 
since a similar inhibition of endothelin action has been demonstrated using H7, a 
PKC inhibitor (Sagiura et al., 1989), and palmitoyl carnitine can also inhibit this 
enzyme (Katoh et al., 1981; Wise & Kuo, 1983). However, there are many potential 
ways in which this compound could interfere with the sustained contraction elicited 
by endothelin, including effects on intracellular calcium movement such as 
inhibition of release from stores. Another instance where relaxant effects of 
palmitoyl carnitine were observed in the present study was in aortae precontracted 
with phenylephrine or high potassium, an effect that appeared to be attenuated in the 
absence of an intact endothelial cell layer. Consequently, it is possible that palmitoyl 
carnitine may possess the ability to stimulate release of endothelium-derived 
relaxant factor (EDRF), in a manner similar to a number of vasoactive compounds 
including acetylcholine, bradykinin and free fatty acids (Furchgott, 1984), which 
would then act on the aortic smooth muscle to produce vascular relaxation. 
However, there is at present no additional evidence to support this hypothesis. In 
fact, certain data cast doubt on the involvement of the endothelium in the action of
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palmitoyl carnitine; firstly, acetylcholine, which causes release of EDRF, produces a 
rapid, smooth relaxation of phenylephrine-precontracted aortae unlike the slower, 
less well-defined response to palmitoyl carnitine, and secondly, relaxation to 
acetylcholine is impaired in tissues precontracted with high potassium (Taylor et al., 
1988), whereas the acyl carnitine still produced a certain degree of vasorelaxation 
under these conditions.
Palmitoyl carnitine elicited a small vasodilator effect in mesenteric vascular 
beds precontracted with phenylephrine, however, the predominant effect was a large 
potentiation of its vasoconstrictor action. Previously it has been demonstrated that 
long chain acyl carnitines can produce an increase in myocardial -adrenoceptor 
numbers (Heathers et al., 1987) and as these compounds readily cross membranes 
(Levitsky and Skulachev, 1972), it is likely that they will have access to the coronary 
circulation and therefore possibly exert similar effects on vascular tissue. The 
vasoconstrictor action of palmitoyl carnitine, when administered as bolus injections 
to the mesenteric vessels, was greatly potentiated in the presence of agonists of both 
ocr  and oc2-adienoceptors, an effect that appeared specific and not merely the result 
of increased tone in the preparation. This potentiation in the presence of clonidine, 
however, may have been mediated via effects at ocj-adrenoceptors since the 
mesenteric vascular bed of the rat is thought to be virtually devoid of post-synaptic 
2_recePtors (Eikenburg, 1984; Yamamoto et al., 1984; Nichols & Hiley, 1985). A 
facilitation of pressor responses to noradrenaline by palmitoyl carnitine has been 
reported in the rat caudal artery (Ugwu et al., 1987), which was partly attributable to 
facilitation of calcium channel function. However, in the present study, the 
potentiation of constrictor responses to palmitoyl carnitine in the presence of <*- 
agonists is unlikely to be a result of direct adrenoceptor stimulation by the acyl 
carnitine since the action of palmitoyl carnitine on the mesenteric vasculature, in the 
absence of any pharmacological agent, was not attenuated by verapamil or 
phentolamine suggesting a site(s) of action distinct from membrane ©c - 
adrenoceptors or voltage-dependent calcium channels. The possibility arises 
therefore that this long chain acyl carnitine may have an alternative mode of action,
64
such as a facilitation of receptor coupling to or a direct interaction with second 
messenger processes, ultimately affecting intracellular calcium movement and 
resultant contractile processes.
However, in contrast to the large potentiation of vasoconstrictor responses to 
palmitoyl carnitine in the presence of perfused o£-agonists, the converse situation 
did not apply i.e. perfused acyl carnitine did not potentiate the responses to bolus 
injections of phenylephrine. Moreover, a concentration of lOpM palmitoyl carnitine 
actually depressed the maximal response to the agonist. Several possibilities exist to 
explain these findings.
This anomaly may have occurred simply as a result of the mode of application 
of drug, in that bolus injections may provide a high, localised concentration of drug 
transiently, whereas perfusions may achieve a more diffuse delivery of drug, 
attaining a steadier equilibrium between free drug in the perfusion medium and that 
interacting with the tissue, perhaps altering the response in several ways. Firstly, as 
long chain acyl carnitines are amphiphiles and thus can insert into biological 
membranes affecting fluidity (Adams et al., 1979j, when delivered as perfusions 
they may be more likely to exert such non-specific effects. Secondly, palmitoyl 
carnitine may induce a tachyphylaxis of the mesenteric vessels when in prolonged 
contact with the tissue thereby depressing its own effects. In fact, the response to 
bolus injections of the drug was reduced with time in the mesenteric vascular bed 
even after a period of 30 minutes washout, and furthermore, this effect may also 
offer an explanation for the lack of action of palmitoyl carnitine on the quiescient 
aorta, where the drug was applied directly into the organ bath, rather than this being 
attributable to any vascular selectivity of the compound.
Alternatively, it may be that palmitoyl carnitine is affecting some aspect of the 
tonic phase of contraction induced by prolonged stimulation of oc-adrenoceptors. 
When administered as bolus injections into the perfusion medium, phenylephrine 
elicits a transient contraction of the mesenteric vasculature i.e. a phasic response, 
however, perfusions of the agonist result in sustained contraction. There are likely to
65
be many differences in the mechanisms underlying these phases of vascular 
contraction and therefore a selective interaction of palmitoyl carnitine with some 
aspect of the tonic phase of mesenteric resistance vessel contraction may also 
account for the apparent discrepancies observed in its action in this preparation.
Palmitoyl carnitine attenuated the actions of both phenylephrine and 
acetylcholine when perfused at lOpM; at this concentration there was a reduction of 
response to higher doses of the agonists and significant depression of the maximum, 
possibly indicating non-specific effects of the amphiphile. Indeed, concentrations in 
excess of lpM produced a marked foaming of the organ bath in isolated aorta 
experiments, suggesting a capacity of the drug to act as a detergent under these 
circumstances. It is worth noting that many of the existing studies involving 
palmitoyl carnitine and related compounds have been carried out at concentrations 
equal to or greater than lOpM, and therefore caution must be exercised in the 
interpretation of such data, albeit that equivalent concentrations of acyl carnitines 
have been reported to occur in the ischaemic myocardium (Liedtke et al., 1978).
In conclusion, palmitoyl carnitine exerts both vasoconstrictor and dilator 
effects exhibiting more profound activity in perfused resistance vessels. Its 
constrictor activity is greatly potentiated in the presence of ©c-agonists, however, 
this does not appear likely to be the result of either direct oc-adrenoceptor 
stimulation or VOC activation.
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CHAPTER 5.
PHARMACOLOGY OF LONG CHAIN ACYL 
CARNITINE ESTERS.
DISCOVERY OF PALMITOYL CARNITINE ETHYL ESTER.
During the course of investigation into the vascular effects of palmitoyl carnitine 
it was decided, for convenience, to make up large batches of drug to be stored in 
solution in heat-sealed ampoules at 0°C. The solvent chosen was chloroform on the 
assumption of it being inert. However, it readily became apparent that prior storage 
of palmitoyl carnitine in this manner altered the pharmacological profile of the drug. 
Before commencing an experiment a fresh ampoule containing palmitoyl carnitine 
solution was thawed, the chloroform removed by bubbling with nitrogen and the 
drug redissolved in distilled water. Instead of the familiar vasoconstrictor response 
to bolus injections of palmitoyl carnitine observed in the isolated Langendorff 
perfused rat heart (fig.28), dose-related reductions in perfusion pressure were now 
observed with the drug that had undergone prior storage in chloroform (fig.28).
It was suggested that it was the 2% ethanol, included in standard laboratory 
chloroform as a stabiliser to prevent phosgene formation, that was reacting with the 
palmitoyl carnitine to form the ethyl ester of the compound (fig.29). This 
‘chloroform-produced* derivative of palmitoyl carnitine was designated PCE. The 
identity of the ethyl ester of palmitoyl carnitine was confirmed by chemical and 
spectroscopic analysis, and unambiguous synthesis of the compound. This novel 
synthetic ester of palmitoyl carnitine was code-named PIE. Following this 
serendipitous discovery some basic variations in structure were investigated, altering 











Figure 28. Typical traces illustrating the effects of palmitoyl carnitine (l-30nmoles) 
(upper) and the 'chloroform-produced' ethyl ester of palmitoyl carnitine, PCE 








Figure 29. Conversion of palmitoyl carnitine to its ethyl ester when stored in 
chloroform (2% ethanol) in heat-sealed ampoules at 0°C. (R= CO(CH2)i4CH3).
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P1M CO(CH2)i4CH3 c h 3
PIE CO(CH2)14CH3 c h 2c h 3
PIP* CO(CH2)14CH3 (CH3)2CH






Bolus injections of PIE, the ethyl ester of palmitoyl carnitine, caused 
dose-related vasodilations in the isolated Langendorff perfused rat heart that were 
both rapid in onset and sustained at higher doses (fig.30). A maximal response was 
produced by lOnmoles of PIE; higher doses produced a smaller fall in perfusion 
pressure preceded in several cases by a transient vasoconstriction possibly reflecting 
a non-specific effect of the drug. Small rises in resting tension were observed on 
addition of bolus injections of PIE and at no time was any effect on heart rate 
recorded.
The vasodilator activities of the synthetic ester PIE and the 
‘chloroform-produced’ equivalent PCE are compared (fig.31a) providing 
pharmacological confirmation of previous chemical and spectroscopic analyses 
suggesting that palmitoyl carnitine was being esterified to PIE while undergoing 
storage in chloroform in heat-sealed ampoules. Figure 31b shows the decrease in 
tension observed with PIE and PCE when applied to the isolated rat heart; again 
both compounds exhibited a similar profile. Having established the identity of the 
novel vasodilator compound, structural variations of the molecule were investigated 
for pharmacological activity, alterations of chemical groups Rj and R2 being made 
(see table 1). Figure 32 shows the effect of increasing the fatty acid chain length by 
2 carbon atoms, from palmitoyl to stearoyl, on vasodilator activity; both the 
maximal dilation elicited and the rate at which the decrease in perfusion pressure 
occurred were smaller with S1E than with PIE (fig.33). Complete removal of the 
fatty acid moiety (IP1), the isopropyl ester of palmitoyl carnitine, or reduction of 
chain length to isobutyryl (PilPi), the isobutyryl ester of isobutyryl carnitine, 
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Figure 30. Effects of PIE (0.1-30nmoles) on heart rate (HR), perfusion pressure 
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Figure 31. Comparison of the effects of the 'chloroform-produced' ethyl ester of 
palmitoyl carnitine (PCE, o) (100%=102.5±5.7mmHg, n -4) and the synthetic ester 
(PIE, •) (100%=95.8±3.5mmHg, n-4) on a) perfusion pressure and b) developed 
tension in the isolated perfused rat heart, expressed as % decrease from basal 
values. Vertical bars represent s.e.mean (*p<0.05).
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Figure 32. Effects of PIE (l-10nmoles) and S1E (l-10nmoles) on perfusion pressure 
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Figure 33. Effects of PIE (•), [100%=95.8±3.5mmHg, n=4] and S1E (o), [100%= 
86.8±9.0mmHg, n -4] on perfusion pressure in the rat isolated Langendorff heart, 
expressed as a) % decrease from basal values and b) rate of response. Vertical bars 
represent s.e.mean (*p<0.05).
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Substitution of the ethyl ester group with methyl (P1M) or isopropyl (PIP1) 
groups did not alter the vasodilator activity of the compounds as markedly as 
altering the fatty acid chain, although a significant reduction in the response elicited 
by P1M compared to PIE or PIP1 was observed with certain doses (0.1-3nmoles) 
(fig.34). A typical trace of the response of the isolated rat heart to PIP1 is shown in 
figure 35, and in view of its potent vasodilator activity this compound was selected 
for use in most of the succeeding experiments investigating possible modes of 
action of the ester derivatives.
A comparison of the synthetic carnitine esters, PIE and PIP1, with known 
vasodilators amyl nitrate, verapamil, cromakalim and iloprost is shown in figure 36. 
Vasodilations of similar magnitude to those elicited by the known agents were 
produced by the novel compounds at comparable doses, however, the duration of 
response was greatest with the carnitine esters.
In order to ascertain the exact concentration range over which PIP1 was exerting 
its vasodilator effects on the coronary circulation, a cumulative concentration- 
response curve to the carnitine ester was performed (fig.37). Increasing 
concentrations of PIP1 (109-10'6M) were perfused through the heart with a contact 
time of 10 minutes per concentration. Constant perfusion of PIP1 decreased 
coronary perfusion pressure in a concentration-related manner and this effect was 
maximal at 0.1 pM. (EC50=16nM, n -4). At these concentrations there was little 
effect on developed tension and no effect on heart rate. However, a supramaximal 
concentration of PIP1 (lOpM) elicited a rise in perfusion pressure (53.5±1.5mmHg) 
and inhibition of developed tension within 16.0±0.3 minutes (data not shown). It is 
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Figure 34. Effects of P1M (A) [100%=92.5±6.7mmHg, n=4], PIE (•), [100%= 
95.8±3.5mmHg, «=4] and PIP1 (o), [100%=104.0±5.0mmHg, n -4] on perfusion 
pressure in the isolated Langendorff perfused heart of the rat, expressed as % 
decrease from basal values. Vertical bars represent s.e.mean (*p<0.05 compared 
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Figure 35. Typical trace showing the effects of PIP1 (0.1-10nmoles) on heart rat 
(HR), perfusion pressure (PP) and developed tension (DT) in the isolated 
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Figure 36. Comparison of the effects of PIE and PIP1 with amyl nitrate (AN), 
verapamil (VER), iloprost (ILO) and cromakalim (CRK) on heart rate (HR), 
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Figure 37. Typical trace showing the effects of cumulative concentrations of PIP1 
(10-9-10’6M) on perfusion pressure (PP) and developed tension (DT) in the isolated 
Langendorff perfused rat heart. Also shown are the mean falls in perfusion pressure 
at each concentration of PIP1 (n=4) (inset). Vertical bars represent s.e.mean.
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b) EFFECT OF AGENTS ON ACTION OF NOVEL COMPOUNDS.
In order to investigate the mechanism of action of the novel vasodilator 
carnitine esters in the Langendorff perfused heart the effect of certain compounds on 
responses to PIP1 and derivatives was examined. The decrease in perfusion pressure 
elicited by a standard dose of PCE (lOnmoles) was dependent on the basal tone of 
the preparation i.e. the greater the resting perfusion pressure the larger the 
vasodilator response (fig.38). This presented a problem when assessing the effect of 
certain agents on the action of the novel compounds. For example indomethacin, a 
cyclo-oxygenase inhibitor, decreased perfusion pressure when perfused through the 
isolated rat heart, and therefore direct comparison of responses to the carnitine 
esters in the presence and absence of the drug proved difficult to interpret.
The following protocol was adopted. Initially a control response to a standard 
dose of PCE (lOnmoles) was obtained and, following recovery from the vasodilation, 
the heart was perfused with indomethacin and the same dose of PCE was added in 
the presence of this drug. The mean results of six such experiments suggest a 
reduction in the action of PCE in the presence of indomethacin; a control mean fall 
of 45.0±7.6mmHg , compared with 26.2±8.2mmHg fall in hearts exposed to 
indomethacin ( |28pM ), however, a similar problem regarding lower basal 
perfusion pressures in the presence of enzyme inhibitor precluded firm conclusions 
about the potential invovement of cyclo-oxygenase products in the action of PCE 
being made. Figure 39 shows a trace obtained from an experiment in which the fall 
in perfusion pressure due to indomethacin ( |28pM ) was not sustained; in this 
instance the response to PCE was not attenuated. Subsequent experiments using 
PIP1 employed a similar protocol comparing the effects of a standard dose of drug 
both in the presence and absence of a pharmacological agent. Table 2 summarises 
the effects of various agents administered in the perfusion medium on the 
vasodilator response to a standard dose of PIP1 (1 nmole).
81
100n






u j  60“ 
IE
dl
z  5 ° -  oH
0) 40"3
Ll
£ 3 0 “ 0.
-J 20“ <
03
35 1 0 '
35 403025201510
DECREASE IN  PERFUSION PRESSURE [mmHg]
Figure 38. Correlation between basal perfusion pressure and the decrease in 
perfusion pressure elicited by a standard dose (lOnmoles) of the 'chloroform- 
produced* ethyl ester of palmitoyl carnitine (PCE) in the isolated Langendorff 
perfused heart of the rat [M).81, p<0.05 («=12)].
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Figure 39. Trace showing the effects of indomethacin | (28pM) on the action of a 
standard dose of PCE (lOnmoles) on perfusion pressure (PP) and developed tension 
(DT) in the isolated Langendorff perfused rat heart.
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Table 2. The effects of various pharmacological agents on the basal perfusion 
pressure and the vasodilator action of PIP1 (Inmole) in the isolated Langendorff 
perfused heart of the rat. (*p<0.05, w=4).
BASAL PERFUSION VASODILATION
PRESSURE (mmHg) (mmHg)
DRUG CONTROL +DRUG CONTROL +DRUG
Flurbiprofen (lOpM) 84.5±2.2 85.814.2 30.811.0 28.514.0
BW755C (lOpM) 81.8±7.6 71.5110.0 25.016.0 17.215.1
Methylene blue (lOpM) 79.8±6.0 66.2112.3 24.813.7 11.016.9
L-NG-nitro arginine (lOOpM) 91.5±5.3 110.017.1 30.811.2 32.812.5
Glibenclamide (lOpM) 76.2±6.6 79219.7 27.214.4 28.018.3
Atropine (50nM) 93.7±5.8 95.312.6 32.314.8 30.311.9
D-Arg bradykinin (lpM) 93.5±7.9 86.014.0 33.016.0 30.516.0
Palmitoyl carnitine (lpM) 76.0±3.0 73.013.0 26.013.5 19.613.0
Palmitoyl carnitine (5pM) 78.012.1 93.015.7 28211.7 0 *
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1) Cyclo-oxygenase/lipoxygenase products.
Two inhibitors of the enzyme cyclo-oxygenase, indomethacin and flurbiprofen, 
were employed to assess whether the vasodilator action of PIP1 was mediated via 
production of prostanoids e.g. prostacyclin, an endogenous smooth muscle relaxant. 
As mentioned previously, indomethacin (lOpg/ml) exerted an effect on coronary 
vascular tone therefore making a direct comparison of PIP1 responses in the 
presence and absence of drug difficult, however, flurbiprofen (lOpM) did not alter 
basal tone of the preparation. In the presence of this inhibitor the vasodilator action 
of PIP1 was not attenuated (fig.40)(table 2).
The effect of the dual cyclo-oxygenase/lipoxygenase inhibitor BW755C 
(lOpg/ml) on the response to PIPi was also examined. The fall in perfusion pressure 
elicited by the isopropyl ester was less, though not significandy, when BW755C 
was present, however, the basal coronary tone was also reduced by the inhibitor 
(table 2).
2) Endothelium-derived relaxant factor(s).
To investigate whether PIP1 was exerting its vasodilator action via a release of 
endothelium-derived relaxant factor (EDRF), an inhibitor of the action of EDRF, 
methylene blue, was used to try to block the responses to the carnitine ester. The 
vasodilator response to PIP1 was smaller in the presence of methylene blue (lOpM), 
however, this is unlikely to be a specific inhibitory effect of the drug because the 
mean perfusion pressure was also lower in the presence of this agent (table 2). In 
one of four experiments the perfusion pressure was not reduced by methylene blue 
but slightly elevated, and in this situation the response to PIP1 was not attenuated 
(fig-41).
In addition, the influence of an enzyme, superoxide dismutase (SOD), which 
prevents the degradation of EDRF by free radicals thereby potentiating its effects, 
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Figure 40. Typical trace showing the effects of flurbiprofen (lOpM) on the action of 
a single dose of PIP* (1 nmole) on perfusion pressure (PP) and developed tension 
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Figure 41. Trace showing the effects of methylene blue (lOpM) on the action of a 
single dose of PIP1 (lnmole) on perfusion pressure (PP) and developed tension (DT) 
in the isolated Langendorff perfused rat heart.
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of 20 & 50 units/ml, produced small, though not significant elevations of resting 
perfusion pressure, however, at these concentrations did not potentiate the 
vasodilator action of PIP1 on the coronary vascular bed. In contrast, the vasodilator 
response to PIP1 was unexpectedly attenuated with both concentrations of SOD 
used; the decrease in perfusion pressure elicited by PIP1 was reduced from 
13.9±2.0mmHg by 4.7±2.1 and 6.3±2.2mmHg in the presence of 20U/ml and 
50U/ml, respectively {n-1).
Finally, the effect of the recently described inhibitor of endothelium-dependent 
vasodilation, L-NG-nitro arginine (L-NOARG) (Moore et al.,1990) was investigated 
on the response to PIP1. Figure 42 shows a typical trace obtained from one such 
experiment. Inclusion of L-NOARG (lOOpM) in the perfusion fluid increased the 
resting tone by 19.5±7.1mmHg, but did not alter the magnitude of vasodilation 
elicited by PIP1 (1 nmole).
3) Potassium channels.
Glibenclamide, a blocker of ATP-sensitive potassium channels (Quast et 
al.,1988), was employed in a similar manner to above to assess any possible 
involvement of such channels in the vascular relaxant action of PIP1. This drug did 
not affect resting perfusion pressure in the hearts tested, and therefore accurate 
comparison of the response to PIP1, in the presence and absence of glibenclamide, 
was possible. The vasodilator action of PIP1 was not attenuated by glibenclamide 
(lOpM) (table 2), a concentration of drug that reduced the response to a submaximal 
dose of BRL38227 (30nmoles) by over 90% (n=4, data not shown).
4) Cholinergic action.
Atropine (5xl0*9M) did not reduce the magnitude of response to PIP1 (table 2). 
At this concentration atropine abolished the vasoconstrictor effects of acetylcholine 
(l-10nmoles) and also the ability of higher doses to transiently cause the heart to 
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Figure 42. Typical trace showing the effects of L-NG-nitro arginine (L-NOARG) 
(lOOpM) on the action of a single dose of PIP1 (1 nmole) on perfusion pressure in 
the isolated Langendorff perfused rat heart.
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5) Bradykinin.
The possibility that PIP1 was acting via stimulation of bradykinin receptors was 
also investigated using the selective bradykinin B2-receptor antagonist D- 
Arg°[Hyp3,Thi5«8,D-Phe7]-bradykinin (Regoli et al.,1990), however, the vasodilator 
action of PIP1 was not significantly altered in the presence of this drug at a 
concentration of lOOnM (table 2).
6) Palmitoyl carnitine.
In view of the similarity in structure and opposite vascular effects of palmitoyl 
carnitine and PIP1, any possible antagonism of the vasodilator action of PIP1 by the 
parent compound was investigated. Figure 43 shows typical traces obtained from 
experiments in which responses to PIP1 were assessed in the presence of either lpM 
or 5pM palmitoyl carnitine. The vasodilation to PIP1 was reduced, though not 
significantly, with lpM palmitoyl carnitine and totally abolished at the higher 
concentration (table 2), however, at 5pM there was also an inability of the coronary 
vasculature to respond to sodium nitroprusside (n=3, data not shown). In addition, 
there was an irreversible depression of developed tension in the heart associated 
with the higher dose of the acyl carnitine; control tension was 5.5±1.0g compared 
with 0.4±0.1g after 10 minutes perfusion with the drug (n=4).
7) Adenosine.
The influence of an enzyme responsible for the breakdown of adenosine, 
adenosine deaminase, on the response to PCE was examined to assess whether PCE 
was exerting its vasodilator action via release of this endogenous metabolite. In the 
perfused rat heart, bolus injections of adenosine (l-30nmoles) caused small, 
transient relaxations of the coronary vasculature in contrast to the larger, more 
sustained vasodilation elicited by PCE (lOnmoles) (fig.44). Adenosine deaminase 
(1 unit/ml) abolished the response to a submaximal dose of adenosine (3nmoles), an 
effect that persisted even after washout. However, the vasodilator action of PCE was
90
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Figure 43. Typical traces showing the effects of lpM {upper trace) and 5pM {lower 
trace) palmitoyl carnitine (PC) on the action of a single dose of PIP1 (1 nmole) on 
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Figure 44. Typical trace showing the effects of adenosine deaminase (1 unit/ml) on 
I the action of adenosine (#, l-100nmoles) and PCE (o,10nmoles) on perfusion 
I pressure (PP) in the isolated Langendorff perfused rat heart.
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not affected by this enzyme; control decrease in perfusion pressure produced by 
PCE (lOnmoles) was 36.0±5.4mmHg compared with 35.0±7.8mmHg in the 
presence of adenosine deaminase (n=4).
8) Phospholipase A2.
Mepacrine (10 7M), which inhibits phospholipase A2 (PLA2) an enzyme 
responsible for membrane phospholipid degradation, reduced the vasodilation 
produced by the methyl ester of palmitoyl carnitine, P1M (0.3nmoles), though not 
significantly; control decrease in perfusion pressure was 14.5±4.6mmHg compared 
with 5.8±2.0mmHg in the presence of mepacrine (n=4). However, at this 
concentration of mepacrine, the response to P1M did not recover to control values 
following a period of washout (7.8±2.0mmHg). It was not feasible to examine 
higher concentrations of mepacrine on the response to P1M, because micromolar 
concentrations produced severe, irreversible depression of developed tension and 
contracture.
c) EFFECT OF PCE ON ^RUBIDIUM EFFLUX.
To further investigate the mode of action of the palmitoyl carnitine derivatives 
the effect of PCE on efflux of radiolabelled rubidium, a marker of potassium 
movement, from preloaded rat hearts, was examined. Figure 45 shows the efflux of 
86Rb from rat hearts, expressed as efflux rate constant (erc/min) with time, elicited 
by single bolus doses of PCE (l-100nmoles). There was no rise in 86Rb efflux 
induced by a bolus injection of 1 nmole of PCE, a dose which produced a 
submaximal relaxation of the coronary vasculature, however, at higher doses (10 & 
100 nmoles) the efflux was transiently increased attaining a maximum within a few 
minutes of drug administration. Further addition of PCE (lOnmoles) to the perfused 
heart, at a point when the coronary bed appeared maximally dilated, produced 
neither a decrease in perfusion pressure nor an increase in 86Rb efflux from the 
tissue (fig.45, bottom trace). The relationship between 86Rb efflux and vasodilation 
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Figure 45. Effects of the 'chloroform-derived' ethyl ester of palmitoyl carnitine 
(PCE) (l-100nmoles) on 86rubidium efflux from isolated Langendorff perfused rat 
heart, expressed as mean efflux rate coefficient (E.R.C.). Doses of PCE 1 nmole 
(top, n=4), lOnmoles (middle, n=4) and lOOnmoles (bottom, n=4) were administered 
at time=0. Additionally, a single dose of PCE (lOnmoles) was added at time=15 
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Figure 46. Comparison of the effects of PCE (l-100nmoles) on perfusion pressure 
(•) in and peak 86rubidium efflux (o) from preloaded isolated Langendorff perfused 
rat hearts (n=4).
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Similar experiments involving the synthetic ethyl ester (PIE), however, have 
failed to provide confirmation of the results obtained with PCE.
d) EFFECT OF EXTRACELLULAR CALCIUM CONCENTRATION.
The effect of changing the calcium concentration of the perfusion solution on 
the action of PCE was assessed in the rat heart. Calcium concentration was 
increased cumulatively from 1.2mM to 4.8mM and then back to 1.2mM for a 
further control response. The data obtained suggest an inverse relationship between 
extracellular calcium concentration and magnitude of vasodilation elicited by a 
standard dose of PCE (1 nmole) (fig.47); the higher the calcium concentration the 


























Figure 47. Effects of cumulatively increasing extracellular calcium concentration 
(1.2-4.8mM) on the vasodilator action of a single dose of PCE (lOnmoles (•)) in the 
isolated Langendorff perfused rat heart. The response to a further dose of PCE 
(lOnmoles) following recovery at 1.2mM [Ca2+] is also shown (o). Vertical bars 
represent s.e.mean (n=4).
97
2) MESENTERIC VASCULAR BED.
a) PRECONTRACTED PREPARATIONS.
In order to examine the effects of the novel carnitine ester PIP1 on the 
mesenteric vascular bed, the basal tone of the preparation first had to be raised 
artificially to allow expression of any vasodilator activity of the drug. This was 
achieved using three |constrictor agents, phenylephrine, endothelin and potassium, 
included in the perfusion medium at a constant concentration.
1) Endothelin.
Figure 48a shows a typical trace of the effect of bolus injections of PIP1 on the 
isolated perfused mesenteric vascular bed of the rat, precontracted with endothelin 
(InM). The peptide, endothelin-1, produced a gradual increase in the basal tone of 
the preparations, reaching a plateau of 90.6±8.0mmHg, and subsequent addition of 
the carnitine ester produced gradual decreases in perfusion pressure reaching a 
maximum at about 30nmoles (fig.48b). Associated with higher doses of the drug 
(>lOnmoles) was a vasoconstrictor action which preceded the fall in vascular tone, 
whilst at supramaximal doses PIP1 elicited solely a pressor response.
2) Phenylephrine.
In those vascular beds that were precontracted with phenylephrine (lOpM), the 
profile of activity of PIP1 was similar (fig.49). Basal tone was raised to 
144.0±12.8mmHg on addition of phenylephrine, and under these conditions the 
isopropyl ester of palmitoyl carnitine produced a relaxant action on the mesenteric 
vasculature with associated constrictor effects apparent at higher doses (>lOnmoles).
3) Potassium.
Resting tone in the preparations was increased to a level of 127.0±13.6mmHg 
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Figure 48. a) Typical trace showing the effects of PIP1 (0.3-300nmoles) on 
perfusion pressure (PP) in the isolated perfused mesenteric vascular bed of the rat 
precontracted with endothelin (InM). b) Vasodilator action of PIP1 in rat mesenteric 
vascular beds precontracted with endothelin (InM), expressed as % cumulative 
decrease in perfusion pressure (100%=61.6±5.5mmHg, n=9).
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Figure 49. Effects of PIP1 (0.3-100nmoles) on perfusion pressure in isolated 
perfused mesenteric vascular beds of the rat precontracted with phenylephrine 
(lOpM), expressed as % cumulative decrease in perfusion pressure (100%= 
120.5±38.9mmHg, /i=5).
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maintain osmolarity), and in these precontracted beds PIP1 induced a dose-related 
fall in perfusion pressure (fig.50). At higher doses of the ester (>lOnmoles) the 
response was clearly biphasic; initially there was a rapid drop in perfusion pressure 
followed by a slower, more sustained relaxation of the mesenteric vessels. However, 
in the presence of high potassium there was not the same degree of vasoconstriction 
associated with higher doses of PIP1, in fact only one dose (300nmoles) exhibited 
this action (fig.50).
In a separate group of experiments the mesenteric vessels were allowed to 
recover from responses to PI Pi before addition of the succeeding dose of drug 
(fig.51), and under these conditions the biphasic vasodilator response was clearly 
seen. Figure 52 illustrates the relationship between the ‘fast’ and ‘slow* components 
of the PIP1 response; both components are dose-related and appear to mirror each 
other.
In addition, the effects of the calcium channel blocker verapamil were 
investigated in potassium depolarised mesenteric vascular beds, and the relaxant 
action compared to that of PIP1 (fig.53). Both agents elicited dose-related 
vasodilation, however, verapamil appeared the more potent drug.
b) EFFECT OF PIPi ON CALCIUM-INDUCED CONTRACTION.
Having established that the synthetic carnitine ester exerted a relaxant action on 
precontracted mesenteric vascular beds, displaying a more rapid effect in 
potassium-depolarised tissues, the possibility that PIP1 was acting via blockade of 
voltage-operated calcium channels (VOCs) was investigated.
Cumulative concentration-response curves were constructed to calcium 
(O.l-lOmM) in potassium-depolarised (llOmM) mesenteric vascular beds, and in 
control preparations the tissue sensitivity did not alter over the experimental period 
(fig.54). The effect of PIP1 on calcium-induced contraction was investigated by 
constructing a control concentration-response curve to calcium chloride and,
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Figure 50. a) Typical trace showing the effects of PIP1 (0.3-300nmoles) on 
perfusion pressure in the isolated perfused mesenteric vascular bed of the rat 
precontracted with high potassium (llOmM). b) Vasodilator action of PIP1 in rat 
mesenteric vascular beds precontracted with high potassium (llOmM), expressed as 
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Figure 51. Typical trace showing the effects of PIP1 (l-100nmoles) on perfusion 
pressure (PP) in the isolated perfused mesenteric vascular bed of the rat 




















Figure 52. Comparison of the 'fast' (•) and 'slow' (o) components of the 
Pip-induced vasodilation of isolated perfused rat mesenteric vascular beds 
precontracted with high potassium (llOmM), expressed as % decrease in perfusion 


















1 0 - 1 1 1 0 - 1 0 1 0 -9 1 0 -710-8
□RUG [moles]
Figure 53. Comparison of the vasodilator effects of verapamil (o, n=6) and PIP1 (•, 
n=4) in the isolated perfused mesenteric vascular bed of the rat precontracted with 
high potassium (llOmM), expressed as % decrease from basal values.
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following washout of the calcium, perfusing the vascular bed with PIP1 (O.l-l.OpM) 
and repeating the cumulative addition of calcium in the presence of the ester 
(fig.55a). PIP1 significantly attenuated the contraction induced by calcium in a 
concentration-dependent manner (fig.55b); at all concentrations of calcium the 
contractile response of the vascular bed was reduced by PIP1.
3) GUINEA-PIG TAENIA-COLI.
a) EFFECT OF PIP1 ON CALCIUM-INDUCED CONTRACTION.
A similar protocol was adopted to assess whether PIP1 exerts an antagonistic 
effect on contractile responses to calcium in the guinea-pig taenia coli preparation 
depolarised with high potassium (llOmM). Figure 56 shows the effect of a single 
concentration of PIP1 (lpM) on the response to calcium in this preparation. There 
was a change in sensitivity of the taenia coli with time, however, the response to 
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Figure 54. Effects of repeated administration of calcium (lO^-lO^M) to rat isolated 
perfused mesenteric vascular beds depolarised with high potassium (llOmM). Data 
expressed as % cumulative increase in perfusion pressure for initial control 
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Figure 55. a) Typical trace showing the effects of PIP1 (0.1 pM) on the increase in 
perfusion pressure elicited by cumulative concentrations of calcium chloride 
(0.1-10mM) in the mesenteric vascular bed of the rat depolarised with high 
potassium (llOmM). b) Effects of O.lpM (A, n=4) and l.OpM fa, n -4) PIP1 on the 
constrictor response to calcium in potassium-depolarised mesenteric vascular beds, 
expressed as % increase in perfusion pressure of maximal response of control curve 
(•, 100%=88.5±7.5mmHg, n=8). Vertical bars represent s.e.mean (*p<0.05).
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Figure 56. Comparison of the effects of lpM PIP1 (A,«=4) on the contractile 
response to calcium in guinea-pig taenia coli depolarised with high potassium 
(llOmM) with that of a time-matched control (o, n-4), expressed as % increase of 





Having examined the effects of PIP1 on fine resistance vessels i.e. the coronary 
and mesenteric vascular beds, the action of PIP1 on the isolated thoracic aorta of the 
rat, prepared as rings, was investigated. In order to assess the vascular relaxant 
effect of the ester, the tissues were first precontracted using either phenylephrine, 
endothelin or high potassium.
1) Phenylephrine.
Aortic rings were precontracted with phenylephrine (10_7M) and the integrity of 
the endothelium assessed by addition of acetylcholine (lpM) to the organ bath; 
tissues that showed less than 80% relaxation were assumed to possess a damaged 
endothelial cell layer and were discarded. In addition, in some experiments the 
endothelium was mechanically removed before examining the effects of PI Pi on the 
aorta.
Phenylephrine (10 7M) produced a rise in tension of 0.46±0.07g and 0.69±0.03g 
in aortic rings with and without an intact endothelial cell layer, respectively. Figure 
57 shows typical traces obtained when PIP1 (0.4-12.8pM) was added cumulatively 
to such precontracted preparations; no appreciable relaxant action of PIP1 was 
observed in either rubbed or unrubbed tissues (fig.58). Additionally, in some 
preparations the tissue was washed following application of PIP1, recontracted to 
phenylephrine (10_7M), and relaxed by addition of papaverine (l-30pM) to confirm 
that mechanical damage of the aorta had not joccurred during the course of the 
experiment (n=3, data not shown).
The effect of altering the potassium concentration of the bathing solution, from 
5.9mM to 3.2mM, on the response of phenylephrine precontracted aortae to PIP1 
was also investigated to examine whether the modified Krebs solution used in 




P E (1 0 -7 M )
16 3 2 6 4 1 2 8P E O O -7 M )
ig
oo
1286 44 8 16 3 221P E ( 1 0 -7 M ) P E (  1 0 -7 M )
Figure 57. Effects of acetylcholine (l-2pM) and PIP1 (0.4-12.8pM) added 
cumulatively on tension(g) in rat thoracic aortic rings with the endothelium either 
intact {upper trace) or artificially removed {lower trace) precontracted with 
phenylephrine (0.1 pM).
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Figure 58. Effects of PIP1 (0.4-12.8pM) on phenylephrine-precontracted rat thoracic 
aortic rings with endothelium intact (•) or artificially removed (o), expressed as % 
relaxation of induced tone (n= 12).
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activity. Similar results to those obtained previously with PIP1 using 5.9mM [K+] 
were found with 3.2mM [K+] in the modified Krebs-Henseleit solution i.e. no 
relaxation was produced by the ester («=4, data not shown).
2) Potassium.
Potassium chloride was also used to precontract aortic rings, and concentrations 
of 80mM and llOmM elicited rises in vascular tone of 0.81±0.08g and 0.86±0.10g, 
respectively. A typical trace illustrating the response to PIP1 (0.5-64pM) in the 
presence of the higher potassium concentration is shown in figure 59. PIP1 caused 
gradual relaxation of potassium-precontracted aortae, exhibiting slightly more effect 
at llOmM than 80mM (-50% peak relaxation compared with -30%, respectively) 
(fig.60).
3) Endothelin.
Endothelin-1 (InM) induced a gradual rise in tension, reaching a plateau level 
(0.46±0.02g) about 20 minutes after inclusion in the organ bath (fig.59). PIP1 
(4-64pM) caused a relaxation of endothelin precontracted preparations reaching 
-60% of the induced tone at the highest concentration used (fig.60).
b) EFFECT ON AGONIST RESPONSE.
The effect of the synthetic carnitine ester PIP1 on the response of the rat aorta 
to two agents, phenylephrine and acetylcholine, was also investigated.
1) Phenylephrine.
Aortic rings were contracted with phenylephrine (10_7M) and, following a 
plateau response to the drug, acetylcholine (lpM) was introduced into the organ 
bath to assess endothelial integrity in a similar manner to that previously described; 
again, less than 80% relaxation of the tissue was taken to be indicative of 
endothelial cell damage and these preparations discarded. The aortae were then
113
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Figure 59. Typical traces showing the effects of PIP1 (0.5-64pM) added 
cumulatively to the organ bath on tension in rat aortic rings precontracted with 
either high potassium (llOmM) (upper trace) or with endothelin (InM) (lower 
trace).
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Figure 60. Relaxant effects of PIP1 (0.5-64.0pM) on rat aortic rings precontracted 
with either 80mM f t  n=4) or llOmM (p, n-4) potassium chloride, or with InM 
endothelin n=3), expressed as % decrease of induced tone.
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washed and, after a recovery period, cumulative concentration-response curves to 
phenylephrine were constructed. Figure 61 shows that sensitivity of the preparations 
did not vary with time.
The effect of PIP1 on the response to phenylephrine was assessed adopting the 
same protocol as above except that, 15 minutes prior to the second concentration- 
response curve to the «>adrenoceptor agonist, the tissue was incubated with a fixed 
concentration of PIP1 and then responses to phenylephrine repeated in the presence 
of the synthetic ester. PIP1 (0.1-lpM) had no effect on the contractile effect of 
phenylephrine, however, a higher concentration of lOpM produced a significant 
attenuation of the response (fig.62); there was a non-parallel shift in the 
concentration-response curve with a depressed maximal contraction to 
phenylephrine.
2) Acetylcholine.
The effect of PIP1 on acetylcholine-induced relaxations of aortic rings, 
precontracted with phenylephrine (107M), was investigated. Tissues were 
precontracted, endothelial integrity assessed as before, washed and allowed to 
recover. Preparations were recontracted with phenylephrine (10_7M) and cumulative 
concentration response curves to acetylcholine constructed; initially a control curve 
was obtained and then further curves in the presence of increasing concentrations of 
PIP1 (0.1-10pM). Concentrations of PIP1 up to lpM did not affect the relaxant 
action of acetylcholine, however, at lOpM the drug significantly attenuated this 
response (fig.63). The response to acetylcholine in the absence of PIP1 did not 
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Figure 61. Effects of repeated addition of cumulative concentrations of 
phenylephrine (5-640nM) on tension in rat thoracic aortic rings, expressed as % 
contraction of the maximal control response. Control (•), 2nd (o) and 3rd (A) 
concentration-response curves were performed allowing 30 minute recovery periods 
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Figure 62. Effects of 0.1 pM (o), l.OpM (A) and lOpM (A) P IP 1 on the contractile 
response of rat thoracic aortic rings to cumulative concentrations of phenylephrine, 
expressed as % contraction of the maximal response of the initial control curve (•, 
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Figure 63. Effects of PIP1 on the relaxation of rat thoracic aortic rings, 
precontracted with phenylephrine (O.lpM), elicited by cumulative concentrations of 
acetylcholine. Data expressed as % relaxation of induced tension in the presence of 
O.lpM (o, 100%=0.67±0.06g), l.OpM (A, 100% = 0.55±0.08g) and lOpM (& 100% 
=0.43±0.08g) PIP1 compared with the initial control response (•, 100%= 




The effect of palmitoyl carnitine and its isopropyl ester, PIP1, on the cardiac 
action potential of guinea-pig papillary muscle was investigated. Initially control 
values of action potential parameters were obtained in the absence of drug (table 3) 
and then, following perfusion of the muscle with a fixed concentration of either 
palmitoyl carnitine or PIP1 for 20 minutes, further impalements were carried out in 
the presence of drug.
Table 3. The Cardiac Action Potential of the Guinea-pig Papillary Muscle (w=40, 
8-12 impalements per papillary muscle).
Parameter. Control value.
Resting membrane potential (RMP) 80.0±0.7mV





(T values represent the time taken for % repolarisation of the action potential 
e.g. 20% (T20))
Palmitoyl carnitine (10-100pM) produced a concentration-related depression of 
the cardiac action potential (fig.64); the resting membrane potential became more
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positive, amplitude decreased in magnitude, and the time taken for the action 
potential to repolarise was reduced. This effect is also illustrated in figure 65 which 
shows a series of action potentials recorded from a single cell, constantly impaled 
for a period of 20 minutes, in the presence of lOOpM palmitoyl carnitine.
In contrast to palmitoyl carnitine, however, PIP1 (lOOpM) was without effect on 
the action potential (fig.66). In view of its lack of action on cardiac muscle, the 
effects of PIP1 on other types of muscle, including both vascular and nonvascular 
preparations, were examined.
b) RABBIT EAR ARTERY.
Resting membrane potential was recorded from ear artery cells for a control 
period, the artery then exposed to PIP1 (lpM) for 20 minutes, and further 
impalements obtained in the presence of drug. In these experiments PIP1 had no 
significant effect on the membrane potential (fig.67), however, the potassium 
channel activator, cromakalim (lpM), caused a large hyperpolarisation of the artery 
when tested using a similar protocol (fig.67); cromakalim altered resting potential 
from -55mV to -80mV.
In order to ascertain whether the isopropyl ester was exerting its action only in 
partially depolarised blood vessels, the effects of PIP1 (l-10pM) was assessed on 
membrane potential in ear arteries already exposed to phenylephrine (lOpM). 
Control impalements were carried out as described earlier, the muscle then exposed 
to phenylephrine for 10 minutes and further recordings made. Following this, 
increasing concentrations of PIP1 (l-10pM) were incorporated into the bathing 
medium containing phenylephrine, and after an equilibrium period of 10 minutes 
additional impalements of drug treated cells were carried out. Figure 68 illustrates 
the depolarising action of the oq-adrenoceptor agonist phenylephrine, which altered 
membrane potential to a new resting level of approximately -33mV. PIP1 (l-10pM) 
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Figure 64. Effects of lOpM ( ^ )  and lOOpM ( ^ )  palmitoyl carnitine on the cardiac 
action potential of guinea-pig papillary muscle, expressed as % decrease from 
control values. Parameters measured are membrane potential (M.POT.), upstroke 
velocity (dV/dt), amplitude (AMP), and the time taken for 20%, 50% and 90% 
repolarisation of the action potential (T20, T50 & T90, respectively). Vertical bars 
represent s.e.mean (*p<0.05, n=40).
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Figure 65. Effects of palmitoyl carnitine (lOOpM) on the cardiac action potential 
measured from a single cell of guinea-pig papillary muscle constantly impaled for a 
period of 20 minutes. Action potentials recorded at 5, 10 and 20 minutes {indicated, 
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Figure 66. Effects of PIP1 on the cardiac action potential from guinea-pig papillary 
muscle, expressed as resting membrane potential (MEMB.POT.) and time taken for 
90% repolarisation (T90) in cells exposed to lOOpM PIP1 {hatched bars) for 20 
minutes compared with control values {empty bars). Vertical bars represent s.e.mean 
(n=30).
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Figure 67. Effects of PIP* (lpM, ^  ) and cromakalim (lpM, E3 ) on resting 
membrane potential recorded from single cells of the rabbit ear artery, compared 



























Figure 68. Effects of lpM ( ^  ) and lOpM ( ) PIP1 on resting membrane
potential recorded from cells of rabbit ear artery depolarised with phenylephrine 
(lOpM, M )• Also shown are initial control values ( □  ) and recovery values 





c) GUINEA-PIG TAENIA COLI.
A similar protocol was adopted for assessment of any action of PIP1 on resting 
membrane potential in the taenia coli preparation of the guinea-pig. Control 
impalements were carried out following an equilibration period, PIP1 (lpM) 
included in the bathing solution and the tissue exposed to drug for 20 minutes 
before further impalements were made. A typical trace of the electrical activity 
recorded from the smooth muscle cells is shown in figure 69a, and it can be seen 
















Figure 69. a) Electrical recordings from cells of the guinea-pig taenia coli in the 
presence of PIP1 (lpM, lower trace) with control impalements {upper trace), b) 
Effects of PIP1 (lpM, hatched bar) on resting membrane potential in guinea-pig 
taenia coli cells, compared with control pre-drug values {empty bar). Vertical bars 
represent s.e.mean {n= 12, 3 preparations).
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6) INFLUENCE OF THE ENDOTHELIUM.
a) CULTURED ENDOTHELIAL CELLS.
Preliminary studies were carried out at the William Harvey Institute (London) 
investigating the effects of PIP1 on cultured bovine aortic endothelial cells. The cells 
were packed into a column perfused with a physiological buffer, and the perfusate 
dripped onto a bioassay cascade comprising rabbit aorta and mesenteric artery, 
denuded of endothelium and precontracted with U46619 (30nM).
Figure 70 illustrates the response of the isolated blood vessels in such an 
experiment. Bradykinin (lng) required injection through the column in order to 
produce a relaxation of the bioassay tissues, and this effect diminished down the 
cascade. In contrast, glyceryl trinitrate was able to exert its relaxant action directly 
on the smooth muscle without prior contact with the endothelial cells. PIP1 
(lOOnmoles) was without effect when applied directly over the tissues, however, 
produced a large, sustained relaxation of the vascular preparations when 
administered through the endothelial cell column. The action of PIP1 diminished 
down the bioassay cascade, suggesting that this compound was exerting its action 
via release of some relaxant factor from the endothelial cells that possessed a short 
duration of action.
This experiment has been repeated, however, further experiments are obviously 
required involving smaller doses, different esters and palmitoyl carnitine itself, 
before firm conclusions can be drawn.
b) EFFECT OF ENDOTHELIAL DAMAGE ON THE VASODILATOR ACTION 
OF PIP1.
Experiments were performed using the mesenteric vascular bed of the rat to 
assess the endothelial dependency of the vascular relaxant action of PIP1 (fig.71). 
Mesenteric vascular beds were precontracted with phenylephrine (lOpM) and, 
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Figure 70. Typical trace showing the effects of PIP1 on EDRF release from cultured 
endothelial cells. PIP1 (lOOnmoles) was administered either directly over bioassay 
tissues (o), comprising rabbit aorta and mesenteric artery, or via a column 
containing bovine aortic endothelial cells (•). Also shown are the effects of 
bradykinin (BK)(lng) and glyceryl trinitrate (GTN)(10ng).
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acetylcholine (0.1-10pmoles) or to PIP* (l-30nmoles). The tissues were washed and 
8mls of air injected through the bed following recovery. Phenylephrine was again 
administered to precontract the preparations and the dose-response to the 
vasodilators repeated in the air-damaged tissues.
Acetylcholine caused a dose-related transient vasodilation in phenylephrine 
precontracted preparations, however, this action was abolished in the air-damaged 
tissues (fig.71), indicating that the endothelial cell layer had been damaged by 
administration of air. PIP*, however, elicited a slower, more sustained relaxation of 
the precontracted mesenteric bed, but this action was not attenuated following 
injection of air, in fact it was slightly potentiated (fig.72).
7) IN  VIVO RESPONSES TO PIP1.
Male Wistar rats were anaesthetised and cannulated for recording of blood 
pressure and heart rate. PI Pi was administered intravenously as bolus injections, via 
the right jugular vein, and a comparison made with the calcium antagonist 
verapamil (fig.73).
PIP* (0.3-lpmoles) induced small, transient falls in blood pressure with 
concomitant decreases in heart rate, whilst at the highest dose used (3pmoles) there 
was also an increase in heart rate following the initial drop. In contrast verapamil 
(50-500nmoles) caused a larger, more sustained hypotensive effect, but also exerted 
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Figure 71. Typical traces showing the effects of damaging the endothelium of rat 
isolated mesenteric vascular beds by air injection on the vasodilator actions of 
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Figure 72. Effects of PIP1 (0.1-3nmoles) on perfusion pressure in control (o) and 
air-damaged (•) isolated perfused rat mesenteric vascular beds precontracted with 
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Figure 73. Typical trace showing the effects of PIP1 (•, 0.3-1.0pmoles) and 





Esterification of the palmitoyl carnitine molecule produced compounds that 
exerted a profound, long-lasting vasodilator action in the perfused rat heart. 
Therefore, a small change in structure fundamentally alters the vascular activity of 
the molecule; PIE and related compounds exhibited essentially opposite effects on 
the coronary circulation to those of the parent drug. Why should such a small 
alteration produce a difference in activity, and how do the novel, synthetic esters of 
palmitoyl carnitine produce their effects?
Firstly, esterification of the parent acyl carnitine removes the negatively 
charged moiety of the compound i.e. the carbonyl group, leaving an overall positive 
charge on the molecule, conferred by the quaternary nitrogen group. In addition, the 
conformation of the molecule will be altered as a consequence. Under physiological 
conditions palmitoyl carnitine will be able to form an internal salt i.e. a Zwitterion 
formed by the interaction of the carbonyl and quaternary nitrogen groups, leaving 
the fatty acyl chain extended like a tail. However, the presence of an ester group in 
the molecule will prevent such an interaction and the conformation will be altered 
accordingly. Preliminary investigation of the structure-activity relationships of the 
molecule suggest that fatty acyl chain length is important with regard to the 
magnitude of vasodilation elicited in the coronary circulation. This may be 
indicative of a receptor mechanism underlying the effects of the esters, or may 
simply relate to the lipophilicity of the compound and hence the ability to 
intercalate into biological membranes. Alteration of the ester function of the 
molecule, however, did not produce such marked changes in activity, possibly 
indicating that the ability of the compounds to produce a vasodilator instead of a 
vasoconstrictor action resides in there not being a free carbonyl group present. The 
fact that there was a slight increase in the activity of the compound with increasing 
carbon length of ester group i.e. PIP1 possessed the greatest coronary dilator action, 
may indicate some ste lie hindrance of the action of an esterase to breakdown the 
drug. Indeed, the duration of action of PIP1 in vivo was transient. Further 
investigation into the structure-activity relationships of the molecule is obviously 
required to attempt to resolve the above problems.
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The mode(s) of action of the novel esters of palmitoyl carnitine remains unclear 
at present in spite of the many routes of investigation carried out in the present 
study, including employment of specific antagonists of known vasodilators in 
isolated vascular preparations, electrophysiological studies and bioassay coupled to 
perfused endothelial cell cultures. However, certain modes of action appear unlikely 
from the data obtained and the possibilities narrowed for future investigation of PIP1 
and related compounds.
For example, the involvement of products of the cyclooxygenase pathway 
appears unlikely in the coronary relaxant action of PIP1 as the vasodilator action of 
this compound in the heart was not affected by flurbiprofen. However, there was no 
concomitant, direct measurement of products released from the heart such as 
6-keto-PGF! to conclusively prove this. Additionally, the specificity of the 
cyclooxygenase inhibitors used is open to question in view of their varying effects 
on perfusion pressure in the perfused heart. For example, indomethacin elicited a 
vasodilator response whereas flurbiprofen was without effect on coronary tone. The 
dual cyclooxygenase/lipoxygenase inhibitor BW755C also produced a fall in 
perfusion pressure, however, this effect may be due to an inhibition of leukotriene 
production, as these products of the lipoxygenase pathway are potent coronary 
vasoconstrictors (Letts & Piper,1982; Roth & Lefer,1983).
In a similar manner, certain agents that were employed to investigate a potential 
role of EDRF in the action of the carnitine esters also produced variable and 
apparently contradictory effects on coronary tone. For example, methylene blue, an 
inhibitor of the actions of EDRF (Martin et al.,1985), caused a drop in perfusion 
pressure in three out of four hearts, whilst superoxide dismutase, which prevents 
EDRF breakdown (Gryglewski et al.,1986), produced a slight elevation in basal 
pressure. The reason(s) for these apparent anomalies is not clear at present, 
however, there have been studies in which the specificity of action of these agents 
has been questioned. For example, SOD does not potentiate the vasodilator effect of 
acetylcholine in either the perfused kidney or mesenteric vascular bed of the rat
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(Bhardwaj & Moore,1988) or its relaxant action in rabbit aorta (Silin et al.,1985) 
casting doubt on the integrity of this compound as a selective pharmacological tool 
for the study of EDRF in perfused organs. In the present study, SOD did not 
potentiate the vasodilator action of PIP1 but actually attenuated it, however, for the 
reasons stated above firm conclusions cannot be drawn from these experiments 
about the involvement of EDRF in the action of PIP1. Similarly, although the 
response to PIP1 was significantly reduced in the presence of methylene blue, in 
three out of four hearts, the selectivity of this effect is questionable. For example 
methylene blue, in addition to its recognised ability to reversibly inhibit the effects 
of endothelium-dependent vasodilators (Martin et al.,1985; Bhardwaj & 
Moore,1988), is also capable of blocking prostacyclin production via a mechanism 
independent of inhibition of soluble guanylate cyclase (Martin et al.,1989). 
Therefore, the results obtained using these compounds in the present study to 
investigate a possible role for EDRF in the action of PIP1 need to be treated 
cautiously.
Perhaps a better agent to employ in this context is the recently described 
inhibitor of EDRF synthesis, L-NG-nitro arginine (L-NOARG), which attenuates 
endothelium-dependent vasodilatation in both rat mesenteric vascular bed and rabbit 
aorta without affecting responses to nitroprusside (Moore et al.,1990), unlike 
methylene blue which inhibits the action of nitrovasodilators (Martin et al.,1985). In 
accord with the study of Moore and co-workers (1990), who observed a constrictor 
action of L-NOARG, this compound produced a significant elevation of coronary 
tone, possibly via inhibition of basal EDRF production thereby indicating a role for 
EDRF in coronary vascular reactivity. L-NOARG did not, however, affect the 
vasodilator response to PIP1, suggesting that this action is not mediated via EDRF 
production.
In contrast, supportive evidence for the involvement of EDRF in the action of 
the carnitine esters came from data obtained using the perfused endothelial cell 
column where PIP1 caused release of some factor from the cultured cells that
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produced relaxation of endothelial denuded bioassay tissues. However, the dose 
required to elicit a response was high i.e. lOOnmoles, and the final concentration 
reaching the cells is unknown. Therefore, since the esters of palmitoyl carnitine are 
amphiphiles and therefore will influence membrane fluidity at sufficient 
concentration, it is possible that they will induce leakage of cellular contents, 
including EDRF, via a non-specific effect rather than an intrinsic action of the 
compounds. Further work is obviously required involving a greater dose range of 
synthetic ester and also control data using other amphiphilic compounds before firm 
conclusions can be drawn from these experiments. The bulk of evidence, however, 
from other experiments seems to suggest that PIP1 and related compounds are not 
exerting their vasodilator action via the stimulation of EDRF production.
For example, in addition to the results obtained in the perfused heart discussed 
above, other experiments have shown that there was no appreciable difference 
between the action of PIP1 in precontracted aortae possessing either an intact or 
mechanically damaged endothelium. Furthermore, PIP1 was able to produce some 
relaxation of aortae precontracted with high potassium, under which conditions the 
relaxant effect of acetylcholine is inhibited (Taylor et al.,1988). However, perhaps 
the most convincing data came from experiments carried out in the perfused 
mesenteric vascular bed where the response to the isopropyl ester of palmitoyl 
carnitine was not attenuated in air-damaged preparations, in contrast to the 
vasodilator responses to acetylcholine which were abolished in such tissues. 
However, histological evidence showing the condition of the endothelial cell layer 
would be beneficial before ruling out the influence of EDRF in the action of PI Pi.
PIP1 does not appear to mediate its vasorelaxant action via the opening of 
potassium channels in a similar manner to cromakalim. Firstly, supramaximal 
concentrations of the ester did not affect resting membrane potential in cardiac, 
vascular |or non-vascular smooth muscle. If the drug were acting via opening of 
potassium channels PIP1 should have elicited a hyperpolarisation of the membrane; 
this clearly was not observed. However, this evidence alone is not sufficient to
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disprove that PIP1 has a site of action distinct from membrane potassium channels 
as the relaxant effect of the drug has not yet been demonstrated in the ear artery 
preparation and its lack of effect on membrane potential may merely reflect a 
selectivity of PIP1. More convincing evidence, however, was obtained from 
experiments in which the coronary dilator action of PIP1 was not attenuated by a 
concentration of glibenclamide that almost completely abolished responses to the 
potassium channel activator BRL38227. The possibility that PIP1 and related esters 
can activate other potassium channels in the coronary circulation cannot be excluded 
at present, especially as PCE was shown to elicit release of radiolabelled rubidium 
from preloaded rat hearts, albeit at high doses. It has been demonstrated that both 
resting and stimulated rubidium efflux from rat aorta do not accurately represent 
potassium movement (Smith et al.,1986) and therefore higher doses of drug may be 
required to demonstrate such effects using rubidium as tracer. For example, 
cromakalim elicits relaxant effects on vascular smooth muscle at lower 
concentrations than are required to stimulate rubidium efflux (Weir & Weston,1986). 
The results of experiments in the present study, however, using PCE to stimulate 
rubidium efflux are inconclusive, since the exact degree of esterification of 
palmitoyl carnitine in the ‘chloroform-produced’ PCE is unknown and thus residual 
effects of the parent drug may be present, and also the results were not reproducible 
using the synthetic compound PIP1. Finally, the fact that PIP1 itself can elicit 
vasodilations in mesenteric vascular beds precontracted with llOmM potassium 
would seem to suggest that it is acting via a mechanism other than activation of 
potassium channels.
Several other possibilities for the mechanism of action of PIP1 seem unlikely 
from the series of experiments carried out in the heart using selective blocking 
agents. For example, the direct stimulation of either bradykinin B2 or muscarinic 
receptors by PIP1 does not appear to account for its coronary vasodilator action as 
responses to this drug were not affected by D-Arg°[Hyp3,Thi5’8,D-Phe7]-bradykinin 
or atropine, respectively. In addition, the potential involvement of phospholipase A2 
in the action of PIP1 was difficult to assess in view of the detrimental effects of the
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enzyme inhibitor mepacrine, which at micromolar concentrations produced 
irreversible damage of the heart. Finally, the effects of PIP1 do not appear to be 
mediated via the release of endogenous adenosine in the heart, however, it is 
assumed in these experiments that adenosine deaminase has access to the smooth 
muscle i.e. the site at which adenosine is produced, and therefore would be able to 
inactivate any adenosine produced in response to PIP1. A preferable future protocol 
would involve use of specific adenosine A2 receptor blockers.
Palmitoyl carnitine has been shown to exert effects on calcium movement, such 
as release from intracellular stores (Messineo et al.,1986) and it has also been 
postulated to be an endogenous membrane channel opener (Spedding & Mir,1987). 
The possibility arises, therefore, that the esters of palmitoyl carnitine may exert 
opposing effects on calcium movement within the cell. PIP1 inhibited the 
vasoconstrictor responses to calcium in the mesenteric vascular bed of the rat 
depolarised by high potassium, indicating an ability of PIP1 to either antagonise 
movement of calcium across the plasma membrane via VOCs or to direcdy affect 
some aspect of the pathway involved in maintainance of tonic contraction. This 
action of PIP1 did not occur in the non-vascular smooth muscle investigated i.e. the 
taenia coli preparation, indicating selectivity in the action of the drug. The coronary 
dilator action of PCE was reduced by raising extracellular calcium, an effect 
consistent with the hypothesis that the esters of palmitoyl carnitine are producing 
their vasodilation via a calcium antagonistic effect, however, increased extracellular 
calcium would also be expected to reduce the effects of any vasodilator indirectly 
by increasing the free intracellular calcium available for contraction. A further 
possibility is that binding of PIP1 is inhibited under such conditions since it has 
been shown that millimolar concentrations of calcium inhibit binding of certain 
calcium antagonists (Garcia etal., 1986).
PIP1 elicited full relaxation of mesenteric vascular beds precontracted with 
either phenylephrine, endothelin or potassium with similar potency, however, in the 
latter case the response to PIP1 was biphasic, comprising an initial fast relaxation
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followed by a slower, more prolonged component. This variation may occur as a 
consequence of the different electrical states of the smooth muscle membrane 
induced by the agonists used to precontract the tissue. For example, the membrane 
potential will have been depolarised by less than 7mV by endothelin (Wallnofer et 
al.,1989), about 30mV by phenylephrine if comparable to noradrenaline (Mulvany et 
al.,1982; Wallnofer et al.,1989) and fully depolarised by llOmM potassium 
(calculated from the Nemst equation). Additionally, the mechanisms involved in 
maintaining contraction in mesenteric resistance vessels by these agents is different; 
high potassium-induced tone is sustained by extracellular calcium influx via VOCs 
(Van Breemen & McNaughton,1970), whereas phenylephrine promotes an influx of 
calcium via predominantly potential-insensitive channels, and the action of 
endothelin remains unclear although certain evidence suggests that contraction is not 
exclusively sustained by calcium influx into the cell (Sagiura et al.,1989). The fact 
that PIP1 exhibited a similar potency in vasodilating mesenteric vascular beds 
precontracted with each of these agents may imply a site of action distal to the 
pathways whereby they raise intracellular calcium to a sufficient level for 
contraction; possibly a direct effect on contractile proteins involved in the 
maintainance of tonic contraction, e.g. interference with ‘latch-state’ (Dillon et 
al.,1981) or other cellular proteins interacting with cytoskeletal structures 
(Rasmussen et al.,1987). Alternatively, the esters of palmitoyl carnitine may be 
exerting effects on calcium extrusion/sequestration mechanisms within the cell, 
however, at present it is only possible to speculate on the mechanism of action of 
PIP1 and related compounds. Interestingly, the fact that there was a biphasic 
response to PIP1 in high potassium-precontracted mesenteric vascular beds may 
suggest more than one mechanism underlying its effects, and therefore is an obvious 
area for further investigation. Finally, it is worth noting that PIP1 was able to cause 
vasoconstriction in this preparation; it seems likely, however, that this is a 
non-specific amphiphilic effect since it loccurred at supramaximal doses when 
complete relaxation of the precontracted tissue had been achieved.
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The effects of PIP1 in the rat aorta occured at much higher concentrations and 
were less profound than those in the heart; a concentration of 0.1 pM PIP1 caused 
almost maximal vasodilation in the perfused heart whilst producing no appreciable 
relaxation of precontracted aortae. It appears, therefore, that PIP1 possesses a 
selectivity for fine resistance vessels. The degree of involvement of intracellular 
calcium release decreases and that of extracellular calcium increases when going 
from conduit to resistance vessels (Cauvin et al.,1982) in the maintainance of 
contraction, possibly indicating some interference of PIP1 with calcium influx into 
the cell. Alternatively, differences may exist between the pathways or agents 
responsible for contraction within the vessels. So far, little investigation of the 
subcellular pathways and contractile apparatus has been carried out in resistance 
vessels, even though this type of blood vessel is more important in the physiological 
regulation of blood flow.
In conclusion, the experiments investigating the mode of action of PIP1 and 
related compounds have produced much negative, and in certain cases inconclusive 
data i.e. where the selectivity of the agent employed is doubtful, but have narrowed 
the possibilities. The action of PIP1 does not appear to be endothelium-dependent 
but an effect on the smooth muscle directly, possibly via more than one mechanism.
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i CHAPTER 7. 
CONCLUSIONS.
The work presented here examin ing the cardiovascular effects of long chain 
acyl carnitines has shown that, far from being a class of compound exerting solely 
non-specific amphiphilic actions, these fatty acid derivatives are capable of 
exhibiting complex profiles of activity on vascular tissue. At present their mode(s) 
of action is unclear, however, the variation in response to palmitoyl carnitine 
between mesenteric vascular beds precontracted with either oc-adrenoceptor agonists 
or endothelin-1, causing a potentiated vasoconstriction or a vasodilation 
respectively, clearly warrants further investigation. The mechanism(s) involved are 
likely to be complicated since related compounds such as palmitoyl 
lysophosphatidylcholine are capable of producing biphasic responses in either 
situation.
Perhaps more interestingly, the current research has led to the discovery of a 
series of novel, vasodilator compounds whose action appears to be selective for 
resistance blood vessels, most notably those of the coronary circulation. Addition of 
the ester group to the acyl carnitine molecule changes its activity from that of a 
predominantly vasoconstrictor compound to a potent vasodilator, also losing the 
marked detrimental mechanical effects on the heart, within its effective 
concentration-range, associated with the parent drug. The underlying mechanism(s) 
of action of these vasodilator derivatives is currently unknown and, although the 
possibilities have been narrowed down by the present research, the scope for further 
investigation appears limitless.
Firstly, exploration of structure-activity relationships of the long chain acyl 
carnitine esters may yield important information about the chemical groups required 
for the molecule to produce vasodilator effects. Basic research in this area has 
already revealed that changing the ester function does not radically alter the capacity 
of the molecule to cause vasodilation, however, the question of whether the change 
in activity from palmitoyl carnitine to that of its ester derivative resides in their not 
being a negatively charged moiety i.e. carboxylic acid group, present should be 
addressed. In order to answer this the ester group could be replaced by another
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function such as an amide or an alkyl group, thereby removing the negative charge, 
leaving the molecule with a net positive charge. Additionally, if these compounds 
still possess dilator activity it is possible that their in vivo action may be more 
prolonged since they will not be potential substrates for esterase enzymes in the 
body.
Alteration of the fatty acid chain length from palmitoyl to stearoyl causes a 
decrease in vasodilator activity. It would be of interest, therefore, to investigate a 
greater spectrum of fatty acyl chain lengths. For example, increasing saturated chain 
lengths from octanoyl (Cg) to icosanoyl (C2 0), including some odd number carbon 
chain lengths and also some unsaturated fatty acids e.g. oleoyl. This will help to 
clarify whether a specific fatty acid chain is important, perhaps to interact 
selectively with a receptor site, or whether a lipophilic group is required to help the 
molecule insert into or pass across a lipid membrane.
Perhaps the most interesting aspect of the molecule to examine is that of the 
positively charged quaternary nitrogen group. It is possible that part or all of the 
vasodilator activity of the ester derivatives resides in a specific interaction of this 
charged group with a receptor site, such as a membrane protein or ion channel, an 
action that is prevented in palmitoyl carnitine by the formation of a Zwitterion. In 
order to investigate this the long chain acyl carnitine ester could be altered to the 
free base i.e. an uncharged molecule. Additionally, the methyl groups on the 
nitrogen atom could be replaced, partially or fully, by larger groups such as ethyl 
and isopropyl, or by smaller hydrogen atoms. Obviously, there are limitless 
alterations that can be made to the basic molecule that are not mentioned above, 
however, further investigation will hopefully lead to a greater understanding of the 
structural features required to produce vasodilation and possibly provide some clue 
to the site of action of these compounds.
Secondly, the acyl carnitine esters appear to be selective for| resistance blood 
vessels such as the mesenteric and coronary vascular beds, whilst having little effect 
in conduit vessels such as the thoracic aorta. It would be interesting to further
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examine the actions of these compounds on other vascular preparations e.g. tail 
artery, perfused kidney, perfused hind-limb, portal vein, and also some non-vascular 
smooth muscle. Additionally, the action of acyl carnitine esters in different species 
should be examined.
Finally, the ultimate goal of future research would be to elucidate the underlying 
mechanism(s) of action of long chain acyl carnitine esters. There is likely to be 
more than one mechanism involved, especially since in high potassium- 
precontracted mesenteric vascular beds, PIPi elicited biphasic relaxations. This 
would therefore be one aspect of the acyl carnitine esters’ vasodilator action to 
investigate further. In addition, another problem that should be resolved is that of 
the apparent ability of these compounds to produce a sizeable release of EDRF from 
cultured aortic endothelial cells yet not appear to mediate their vasodilator activity 
in isolated vascular preparations via such a release. As mentioned previously, 
further experimentation with cultured cells is required.
Other possible areas of investigation include the use of cultured cells or cellular 
fractions such as sarcoplasmic reticulum, to examine the effects of acyl carnitine 
esters on intracellular calcium movement, employing fluorescent probes or 
radiolabelled tracers, or work with enzymes such as protein kinase C, recently 
shown to be stimulated or inhibited by a number of lipid-containing compounds, the 
effect dependent on the charge of the molecule {Epand & Lester, 1990). Similarly, 
other potential targets for PIP1 and related compounds are G-proteins, which are 
also modulated by cationic amphiphilic molecules, possibly via a receptor- 
independent mode of action (Mousli et al.,1990). Lastly, to further explore the 
relevance of the positive charge to the activity of the acyl carnitine esters, the 
effects of highly negatively-charged compounds such as heparin and dextran 
sulphate on the response to PIP1 in the heart could be investigated, since they are 
able to abolish endothelium-dependent vascular relaxations to polycations (‘Thomas 
et al.,1989b).
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In conclusion, acyl carnitine esters are a new and interesting series of 
vasodilator compounds whose mechanism of action is at present unknown. Their 
mode of action does not appear to conform to that of many currently investigated 
drugs. At present, however, the potential therapeutic value of these compounds for 
the treatment of cardiovascular disorders appears doubtful when considering many 
factors such as the lability of the ester group of the molecule, the problem of 
absorption of many charged quaternary amines and the possible metabolism of acyl 
carnitine esters to their parent acyl carnitine. It is more likely that any possible 
benefit of these compounds will derive from their use as pharmacological tools for 
investigation into the underlying mechanisms of regulation of vascular tone, 
potentially highlighting further differences between resistance and conduit vessels.
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